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ABSTRACT
HEXOSAMINE SALVAGE IN PANCREATIC CANCER

Sydney L. Campbell
Kathryn E. Wellen

Tumors of many types exhibit aberrant glycosylation, which can impact cancer
progression and therapeutic responses. The hexosamine biosynthesis pathway (HBP)
branches from glycolysis at fructose-6-phosphate to synthesize uridine diphosphate Nacetylglucosamine (UDP-GlcNAc), a major substrate for glycosylation in the cell. HBP
enzyme gene expression is elevated in pancreatic ductal adenocarcinoma (PDA), and
studies have pointed to the potential significance of the HBP as a therapeutic target. Yet,
the PDA tumor microenvironment is nutrient poor, and adaptive nutrient acquisition
strategies support tumorigenesis. Here, we identify that pancreatic cancer cells salvage
GlcNAc via N-acetylglucosamine kinase (NAGK), particularly under glutamine limitation.
Glutamine deprivation suppresses de novo HBP flux and triggers upregulation of NAGK.
NAGK expression is elevated in human PDA. NAGK deletion forces PDA cells to rely
on de novo UDP-GlcNAc synthesis and impairs tumor growth in mice. Together, these
data identify an important role for NAGK-dependent hexosamine salvage in supporting
PDA tumor growth.
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CHAPTER 1: Metabolites as signaling molecules in cancer
Introduction
The capacity of cells to sense nutrients and modulate their activities accordingly
is central to life and to normal cellular function. Cancer cells face diverse metabolic
challenges, including nutrient-limited microenvironments, changing environmental
conditions during tumor progression and metastasis, and exposure to cancer treatments
that directly or indirectly impact metabolic pathways. Understanding how cancer cells
assess their metabolic resources to adapt to these challenges could lead to improved
cancer therapeutic strategies.
Cells monitor nutrient availability through the core nutrient sensing AMPactivated protein kinase (AMPK) and mechanistic target of Rapamycin (mTOR)
pathways (Ben-Sahra and Manning, 2017; Garcia and Shaw, 2018; Hardie et al., 2016;
Saxton and Sabatini, 2017). Additionally, transcription factors such as sterol response
element-binding protein (SREBP) and carbohydrate response element-binding protein
(ChREBP) have well-described roles in cholesterol- and glucose-dependent gene
regulation, respectively (Abdul-Wahed et al., 2017; DeBose-Boyd and Ye, 2018).
Extensive study of these pathways has led to fundamental insights into physiology and
disease. However, in addition to these major nutrient-sensing pathways, metabolite
abundance can be sensed by the cell via post-translational modifications, since many of
the enzymes that establish these modifications utilize metabolites as substrates. Such
modifications include acetylation (using acetyl-CoA as the acetyl donor), methylation
(requiring S-adenosylmethionine [SAM]), and O-GlcNAcylation (employing uridine
diphosphate N-acetylglucosamine [UDP-GlcNAc]) (Figure 1). Importantly, many of these
metabolite substrates appear to be present at levels in cells that can limit enzyme
1

reaction rates (Fan et al., 2015; Reid et al., 2017). Nutrient-sensitive protein or chromatin
modifications thus have the potential to modulate gene expression in accordance with
metabolic resources.
In order to support growth and proliferation, cancer cells remodel metabolism to
enable synthesis of lipids, proteins, and nucleic acids. Moreover, flexibility in nutrient
acquisition and utilization enables tumor cells to adapt and survive when faced with
nutrient scarcity. These metabolic alterations have the potential to impact chromatin
modification and gene expression and thereby to modulate cellular functions (Pavlova
and Thompson, 2016). Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations in
cancer are clear examples in which metabolic alterations drive malignant phenotypes at
least in part through changes in chromatin modification. Gain-of-function mutations in
IDH1 and IDH2 lead to production of (D)-2-HG, which inhibits α-ketoglutarate-dependent
dioxygenases, including JMJD histone demethylases and TET enzymes (Ye et al.,
2018). Intense efforts to target these enzymes are underway, and recent clinical trials in
acute myeloid leukemia patients treated with inhibitors targeting mutant IDH1 or mutant
IDH2 show some patients responding for a period of several months (DiNardo et al.,
2018; Stein et al., 2017). In addition to IDH mutation, metabolic alterations driven by
oncogenic metabolic reprogramming or by nutrient availability have the potential to alter
signaling and epigenetics in cancer cells to impact tumor formation or growth. The next
sections will discuss how availability of specific metabolites can signal to the nucleus
through regulation of chromatin modifications or transcription factor activities, focusing
on acetyl-CoA, SAM, UDP-GlcNAc, and the TCA cycle intermediates α-KG, succinate,
and fumarate. For each of these metabolites, we will examine how metabolic
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perturbations in cancer alter these signals to contribute to tumorigenesis and cancer
progression.
Acetyl-CoA
Acetyl-CoA is both a central metabolic intermediate and the acetyl donor for
acetylation reactions, positioning it at the crossroads of metabolism and signaling
(Sivanand et al., 2018). In mitochondria, acetyl-CoA is generated from several sources,
including pyruvate, acetate, fatty acid β-oxidation, and amino acid catabolism.
Mitochondrial acetyl-CoA is required for citrate synthesis in the TCA cycle. Since acetylCoA cannot pass through mitochondrial membranes, it must be synthesized separately
in other subcellular compartments. It is produced in the cytosol and nucleus from
mitochondria-exported citrate by ATP-citrate lyase (ACLY), as well as from acetate by
acyl-CoA synthetase short-chain family member 2 (ACSS2) (Sivanand et al., 2018). The
pyruvate dehydrogenase complex (PDC), which converts pyruvate to acetyl -CoA, also
translocates from the mitochondria to the nucleus under certain conditions, such as in
response to mitochondrial stress or during specific developmental phases (Nagaraj et
al., 2017; Sutendra et al., 2014). Acetyl-CoA is needed in the cytosol for biosynthetic
processes, including de novo fatty acid and cholesterol synthesis, and is also used for
post-translational lysine (Nε) acetylation throughout the cell. Acetyl-CoA thus serves
critical functions both in metabolism and in cell signaling.
Acetyl-CoA levels rise and fall with nutrient abundance, and thus it has been
proposed that acetyl-CoA concentration may serve as a signal to the cell of nutrient
abundance (Shi and Tu, 2015; Sivanand et al., 2018). Acetyl-CoA concentrations are
approximately 3–20 μM in mammalian cells (Chen et al., 2016; Lee et al., 2014), which
could potentially limit the activity of some lysine acetyltransferases (KATs) such as p300,
3

which has a reported Km for acetyl-CoA within this range (6.7 μM) (Fan et al., 2015; Liu
et al., 2008). Moreover, many KATs are inhibited by their product CoA, and the acetylCoA:CoA ratio may also be important in regulating acetylation in response to metabolic
changes (Fan et al., 2015; Lee et al., 2014; Montgomery et al., 2015). Nutrient limitation
or glycolytic inhibition leads to decreased acetyl-CoA levels and in turn reduced histone
and non-histone protein acetylation (Cluntun et al., 2015; Lee et al., 2014; Mariño et al.,
2014; Wellen et al., 2009). Consistent with the proposed role of acetyl-CoA in nutrient
sensing, genes related to cell growth are prominently acetyl-CoA responsive in yeast
(Cai et al., 2011), and in both yeast and mammalian cells, cell cycle gene expression is
linked to acetyl-CoA abundance (Lee et al., 2014; Lei and Tu, 2013). Acetyl-CoA has
been associated with promoting metabolic gene expression for nutrient uptake and
macromolecular biosynthesis and with suppressing catabolic metabolism. For example,
in adipocytes, expression of Slc2a4, encoding the glucose transporter GLUT4 as well as
other glycolytic genes, is acetyl-CoA responsive (Wellen et al., 2009; Zhao et al., 2016),
suggesting that glucose-dependent acetyl-CoA production may mediate a positive
feedback loop supporting glucose uptake and metabolism in this cell type (Figure 2A).
Similarly, in hypoxic liver cancer cells, acetyl-CoA production from acetate is linked to
epigenetic control of lipid biosynthesis gene expression (Gao et al., 2016). Conversely,
acetyl-CoA abundance suppresses autophagy, a major catabolic process in the cell, in a
p300-dependent manner (Mariño et al., 2014). Thus, signaling roles of acetyl-CoA
appear to be broadly involved in cellular responses to high nutrient abundance.
In addition to nutrient availability, oncogenic signaling and microenvironmental
conditions such as hypoxia regulate acetyl-CoA production and utilization, impacting its
use in biosynthetic processes and its roles in signaling. For example, MYC expression
4

increases glucose-dependent fatty acid synthesis and histone acetylation (Morrish et al.,
2009). AKT phosphorylates ACLY at serine 455, enhancing its activity (Berwick et al.,
2002; Potapova et al., 2000), and expression of constitutively active AKT promotes
acetyl-CoA production and histone H3 and H4 acetylation in cancer cells (Lee et al.,
2014). In human gliomas and prostate tumors, pAKT-S473 and global histone
acetylation levels positively correlate (Lee et al., 2014). Thus, oncogenic signaling
generally promotes ACLY-dependent acetyl-CoA production and utilization. Hypoxia
conversely suppresses glucose-dependent fatty acid synthesis and histone acetylation
but stimulates ACSS2 upregulation and acetate use in these processes (Gao et al.,
2016; Schug et al., 2015). Both ACLY and ACSS2 expression are upregulated in
multiple cancer types, and genetic or pharmacological targeting of these enzymes
produces anti-cancer effects in preclinical models (Comerford et al., 2014; Hatzivassiliou
et al., 2005; Migita et al., 2008; Schug et al., 2015).
A key question arising from these studies is how the availability of acetyl-CoA
can regulate histone acetylation at specific loci and expression of distinct sets of genes.
Two interrelated themes that may explain this specificity in gene regulation are
beginning to emerge: (1) spatiotemporal control of acetyl-CoA production within the
nucleus (Figures 3A and 3B) and (2) transcription factor regulation in response to acetylCoA (Figure 3C). These models are expanded upon below.
Spatiotemporal control of acetyl-CoA production within the nucleus

ACLY, ACSS2, and PDC have each been found within nuclei of cancer cells
(Comerford et al., 2014; Sutendra et al., 2014; Wellen et al., 2009), suggesting that they
may have distinct roles there. Findings from recent studies suggest that dynamic post5

translational modification of these enzymes within the nucleus or their association with
KATs and transcription factors may account for their roles in chromatin regulation. For
example, ACLY is phosphorylated within the nucleus in response to DNA damage
signaling, where it promotes histone H4 acetylation near sites of DNA double-strand
breaks, thus enabling BRCA1 recruitment and DNA repair by homologous recombination
(Sivanand et al., 2017). Dynamic ACLY phosphorylation may allow a rapid increase in
the capture and cleavage of citrate in the nucleus when demand for acetyl -CoA rises in
response to a stimulus such as DNA damage (Figure 3A).
ACSS2, on the other hand, has been shown to be recruited to specific genomic
loci to supply acetyl-CoA for site-specific histone acetylation. For example, ACSS2
nuclear localization and chromatin recruitment participates in neuronal gene regulation,
in which ACSS2 associates with the KAT p300 and facilitates expression of neuronal
identity genes (Mews et al., 2017). Similarly, in glioblastoma cell lines, ACSS2 was
found to translocate to the nucleus under low-glucose conditions upon phosphorylation
by AMPK. In the nucleus, ACSS2 binds transcription factor EB (TFEB) to facilitate
adaptation to low glucose by promoting expression of lysosomal biogenesis and
autophagy-related genes (Li et al., 2017). Since cellular acetyl-CoA levels fall when
glucose is limited (Lee et al., 2014), it is possible that a localized source of acetyl-CoA
generated by ACSS2 is particularly important in this context to ensure adequate
substrate availability to KATs for histone acetylation. Moreover, given the role of ACSS2
in recapturing acetate produced by HDAC reactions (Bulusu et al., 2017), chromatin
localization of this enzyme may allow for the efficient redistribution of acetylation marks
for gene regulation (Figure 3B).

6

Nuclear functions of PDC have also recently been implicated in gene regulation.
In prostate cancer, nuclear PDC facilitates H3K9 acetylation at promoter regions of
lipogenic genes, including ACLY and SQLE, promoting lipogenesis and supporting cell
proliferation (Chen et al., 2018). Nuclear PDC has also been found in association with
STAT5A in adipocytes (Richard et al., 2017), as well as with the arylhydrocarbon
receptor in HeLa cells (Matsuda et al., 2016). Thus, accumulating evidence suggests
that compartmentalized acetyl-CoA metabolism facilitates histone acetylation for gene
regulation and DNA repair. A more in-depth discussion of the roles of spatial and
temporal control of acetyl-CoA metabolism can be found in Sivanand et al., 2018.
Transcription factor regulation in response to acetyl-CoA

Emerging evidence suggests that acetyl-CoA abundance can influence gene
expression through regulation of transcription factors (Figure 3C). Lysine acetylation is a
highly prevalent post-translational modification found on thousands of sites across
cellular proteins, including many transcription factors and coregulators as well as
chromatin-modifying and remodeling enzymes (Choudhary et al., 2014). Acetylation can
impact the function of a transcription factor by altering its stability, its subcellular
localization, or its ability to bind to DNA (Choudhary et al., 2014). In breast cancer,
acetyl-CoA abundance promotes acetylation and nuclear translocation of SMAD2, upon
which SMAD2 activates expression of transcription factors SNAIL and SLUG, increasing
cell invasion capabilities. Inhibition of acetyl-CoA carboxylase (ACC) 1, which
synthesizes malonyl-CoA from acetyl-CoA to initiate fatty acid synthesis, results in
increased acetyl-CoA levels and, in turn, SMAD2 acetylation and increased metastasis
(Rios Garcia et al., 2017). Similarly, metformin treatment of cancer cells results in
AMPK-dependent ACC inhibition, corresponding with increased H3 and H4 histone
7

acetylation as well as increased acetylation of the p65 subunit of the transcription factor
NF-κB and expression of NF-κB target genes (Galdieri et al., 2016). Transcription factor
acetylation may also be tied directly to specific acetyl-CoA producers in some contexts;
for example, CBP-mediated hypoxia-inducible factor (HIF)-2α acetylation in hypoxia is
dependent on ACSS2 (Xu et al., 2014).
In addition to direct regulation by acetylation, transcription factor activity can be
influenced by acetyl-CoA concentration through indirect mechanisms. In glioblastoma
cells, acetyl-CoA availability promotes cell migration and adhesion to the extracellular
matrix in a manner dependent on the Ca2+-responsive transcription factor NFAT1.
Acetyl-CoA abundance corresponds with increased intracellular Ca2+ levels, promoting
Ca2+-dependent NFAT1 nuclear translocation when acetyl-CoA is abundant (Lee et al.,
2018). NFAT transcription factors operate in conjunction with the KATs p300/CBP
(Garcia-Rodriguez and Rao, 1998), and ChIP-seq analysis demonstrated potent acetylCoA-dependent regulation of H3K27 acetylation at the promoters of cell adhesion genes
(Lee et al., 2018). Thus, acetyl-CoA-dependent coordination of transcription factor
activity is one mechanism through which specific sets of genes are regulated in
response to nutrient abundance or metabolic alterations.
One carbon metabolism: S-adenosylmethionine
The methylation of histones and DNA requires the one-carbon donor SAM, which
is produced in the methionine cycle. SAM is synthesized from methionine and ATP by
methionine adenosyltransferase (MAT). After transfer of the methyl group from SAM to
the substrate, S-adenosyl homocysteine (SAH) is produced along with the methylated
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substrate. SAH is then converted to homocysteine, and finally methionine is regenerated
after donation of a methyl group from 5-methyl-tetrahydrofolate (THF) (Locasale, 2013).
Methylation of histones and DNA is sensitive to the abundance of SAM or the
[SAM]:[SAH] ratio, since SAH can act as an inhibitor of methyltransferases and the Km
and Ki for SAM and SAH, respectively, of many methyltransferases falls within
physiological range (Reid et al., 2017). Restricting methionine in cultured cells markedly
suppresses levels of SAM and SAH. This coincides with decreased global methylation of
several histone lysines, with H3K4me3, a chromatin mark generally associated with
open chromatin and active transcription, the most sensitive (Mentch et al., 2015).
Interestingly, the genome-wide locations of H3K4me3 peaks remain consistent upon
methionine restriction, while peak width at specific genes is sensitive to methionine
availability in cancer cells (Dai et al., 2018). Peak width correlates closely with gene
expression, and methionine-responsive genes in colon cancer cells include those
involved in cell cycle and cancer-related pathways (Dai et al., 2018). Understanding the
impact of such regulation on tumorigenesis awaits further study. Notably, however,
metabolic regulation of histone methylation is observed in vivo; upon consumption of a
methionine-restricted diet, SAM and global H3K4me3 levels decrease in the livers of
mice (Mentch et al., 2015). Thus, methionine availability impacts SAM levels and histone
methylation in vitro and in vivo.
Intracellular methionine concentration is also impacted by the controlled
expression of cell surface transporters. Methionine can be transported into cells through
the amino acid transporter LAT1 (SLC7A5), which forms a heterodimer with SLC3A2
(Napolitano et al., 2015). Expression of LAT1 and SLC3A2 are regulated by MYC (Gao
et al., 2009; Hayashi et al., 2012; Wang et al., 2011), and the cell surface localization of
9

SLC3A2 is responsive to AKT-mTOR signaling (Edinger and Thompson, 2002),
suggesting that many cancer cells may upregulate the import of methionine and other
amino acids. In a lung cancer cell line, those cells with high expression of LAT1 exhibit
increased abundance of SAM, elevated activity of the histone methyltransferase EZH2
and higher H3K27me3 levels, and enhanced subcutaneous tumor growth compared to
those cells with low LAT1 expression. Silencing of LAT1 or MAT2A suppresses
H3K27me3 and tumor growth (Dann et al., 2015). Interestingly, expression of LAT1 itself
is enhanced by EZH2 activity, suggesting a positive feedback loop that further drives
methionine uptake to sustain EZH2 activity (Figure 2B). These data indicate that
controlling the uptake of methionine into cells can regulate SAM and histone methylation
levels.
Serine metabolism is also an important determinant of SAM levels. Serine is a
one-carbon donor to the folate cycle and allows the regeneration of methionine for SAM
synthesis. Serine conversion to glycine by serine hydroxymethyltransferase (SHMT)
generates 5,10-methylene-THF, which

is subsequently reduced by methylene

tetrahydrofolate reductase (MTHFR) to 5-methyl-THF within the folate cycle(Locasale,
2013). As mentioned earlier, methionine is regenerated by 5-methyl-THF donating a
methyl group to homocysteine (Figure 4A). Along with allowing regeneration of
methionine, serine can also impact the SAM cycle by supporting synthesis of ATP, which
is required for generation of SAM from methionine (Maddocks et al., 2016). Consistent
with this demand for serine, a diet restricted in serine and glycine can limit growth of
certain cancers, such as MYC-driven lymphoma or intestinal cancer driven by APC
inactivation (Maddocks et al., 2017).
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In addition to serine uptake, serine levels can also be increased via regulation of
its synthesis from the glycolytic intermediate 3-phosphoglycerate. Amplification of the
gene encoding phosphoglycerate dehydrogenase (PHGDH), the first enzyme in the de
novo serine biosynthesis pathway, occurs in several cancers including breast cancer
and melanoma (Locasale et al., 2011; Possemato et al., 2011). Increased serine
biosynthesis is also driven by histone methyltransferase EHMT2 (G9A) overexpression
in osteosarcoma. Knockdown of EHMT2 in U2OS cells results in decreased H3K9me1 at
the

promoter

regions

of

the

genes

encoding

PHGDH

and

phosphoserine

aminotransferase (PSAT), the second enzyme in the serine biosynthesis pathway,
reducing their expression and downregulating de novo serine synthesis. Overexpression
of EHMT2 increases growth of U2OS cell subcutaneous tumors in a manner dependent
on increased serine biosynthesis (Ding et al., 2013). These data suggest that, similar to
EZH2 and regulation of LAT1, EHMT2 expression may engage a positive feedback loop
to increase serine synthesis to provide SAM as a substrate for EHMT2. Finally,
enhanced serine synthesis has been observed in the context of Kras and Lkb1
mutations in pancreatic cancer, in which serine biosynthesis genes, including Psat, are
upregulated. PSAT silencing in pancreatic cancer cells decreases SAM abundance and
in turn DNA methylation at long interspersed nuclear (LINE) elements, increasing their
expression. These findings uncovered a therapeutic vulnerability: subcutaneous tumors
generated from cells with Kras and Lkb1 mutations exhibit enhanced sensitivity to DNA
methyltransferase inhibition (Kottakis et al., 2016). Thus, serine biosynthesis is
upregulated by several distinct mechanisms in cancer cells and may impact the
regulation of histone or DNA methylation, pointing to potential metabolic and epigenetic
vulnerabilities in these tumors.
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Analogous to the growing evidence for coordination of local acetyl-CoA
production within the nucleus (Figures 3A and 3B), recent evidence argues that nuclear
SAM production may also be important for regulation of specific genes. In yeast, SAM
synthesis enzymes were identified within a serine-responsive, chromatin-associated
complex termed SESAME that regulates locus-specific histone methylation(Li et al.,
2015). Moreover, in liver cancer cells, nuclear MATII associates with the DNA-binding
protein MafK, where it provides substrate for histone methyltransferases to regulate
MafK target genes (Katoh et al., 2011). Further study is required to determine the exact
roles of these MAT-chromatin modifier interactions in cancer.
The hexosamine biosynthesis pathway: UDP N-acetylglucosamine
The hexosamine biosynthetic pathway (HBP) produces nucleotide sugars that
are substrates for glycosylation (Figure 4B). The HBP branches off of glycolysis from
fructose-6-phosphate, which is converted to glucosamine-6-phosphate using glutamine
as the nitrogen donor. Glucosamine-6-phosphate is acetylated, generating Nacetylglucosamine-6-phosphate (GlcNAc-6-phosphate), which is then converted to
GlcNAc-1-phosphate and finally attached to the nucleotide UTP, generating UDP-Nacetylglucosamine (UDP-GlcNAc) (Denzel and Antebi, 2015; Ferrer et al., 2016). UDPGlcNAc is a key substrate for both N- and O-linked glycosylation, as will be discussed
below, and it is also used for synthesis of UDP-N-acetylgalactosamine (UDP-GalNAc)
and CMP-sialic acid, other important substrates for production of glycoproteins (Denzel
and Antebi, 2015). As the HBP takes inputs from several major metabolic pathways in
the cell, and because flux into the pathway is impacted by both glucose and glutamine
metabolism (Araujo et al., 2017; Wellen et al., 2010), the HBP has been proposed as a
nutrient-sensing pathway (Ferrer et al., 2016; Hardivillé and Hart, 2014). Moreover,
12

metabolic reprogramming by c-MYC, mutant KRAS, or hypoxic conditions increases flux
into the HBP (Guillaumond et al., 2013; Morrish et al., 2009; Ying et al., 2012), and
genetic or pharmacological targeting of HBP enzymes has been found to suppress
proliferation, cell migration, and tumor growth (Ricciardiello et al., 2018; Ying et al.,
2012). Thus, the HBP supports malignant phenotypes, and both nutrient availability and
metabolic reprogramming can impact HBP activity.
The O-GlcNAc modification is a single O-linked GlcNAc post-translational
modification to serine and threonine residues. O-GlcNAc modifications are added by a
single enzyme, O-GlcNAc transferase (OGT), and removed by a single enzyme, OGlcNAcase (OGA). O-GlcNAcylation is upregulated in many cancers, including breast,
prostate, and pancreatic, and silencing of OGT suppresses proliferation and tumor
growth(Caldwell et al., 2010; Lynch et al., 2012; Ma et al., 2013; Sodi et al., 2018).
Glucose-dependent O-GlcNAcylation is sufficient to enhance oncogenic signaling and
drive malignant phenotypes, such as loss of polarity in breast epithelial cells(Onodera et
al., 2014). High cellular O-GlcNAcylation in cancer cells also results in diminished α-KG
levels, thus reducing HIF-1α prolyl hydroxylation (an α-KG-dependent reaction) and
enhancing HIF stability, promoting expression of target genes such as GLUT1. This
promotes sustained high rates of glycolysis, suggesting that cancer cells engage a
feedforward metabolic signaling loop via the HBP to sustain oncogenic metabolic
features(Ferrer et al., 2014) (Figure 2C). O-GlcNAcylation is also implicated in other
processes that support tumor growth, including augmenting lipid biosynthesis by
regulating SREBP in an AMPK-dependent manner(Sodi et al., 2018) and promoting
expression and stabilization of HSP70 and HSP90 to combat proteotoxic stress(Zachara
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et al., 2004). These data indicate that tumors may maintain high O-GlcNAcylation to
support various processes that enable tumor growth.
Although in many cases the specific O-GlcNAcylated proteins that mediate
particular oncogenic phenotypes are not known, recent studies have delineated roles for
distinct O-GlcNAcylation events. For example, in pancreatic cancer cells, the
transcription factor YAP is O-GlcNAcylated in a glucose-dependent manner, promoting
its nuclear localization, association with its partner TEAD, and transcription of its target
genes. Expression of a mutant form of YAP that cannot be O-GlcNAcylated in pancreatic
cancer cells impairs subcutaneous tumor growth (Peng et al., 2017). Similarly, the
KEAP1/NRF2 pathway, which is involved in antioxidant gene regulation, is regulated by
O-GlcNAcylation in a glucose-dependent manner. The adaptor protein KEAP1 is OGlcNAcylated, which promotes its association with the E3 ligase CUL3 and subsequent
ubiquitination and degradation of NRF2. Thus, under nutrient-limited conditions, reduced
KEAP1 O-GlcNAcylation promotes NRF2 transcriptional activity and resistance to
oxidative stress (Chen et al., 2017a). Through mechanisms such as these, OGlcNAcylation links glucose availability to transcriptional regulation.
Nutrient-sensitive changes in N-linked glycosylation can also impact nuclear
gene expression. The availability of UDP-GlcNAc impacts N-glycan branching and
surface expression of growth factor receptors, thus sustaining high levels of signaling
(Lau et al., 2007; Wellen et al., 2010). In addition, UDP-GlcNAc-dependent Nglycosylation of SREBP cleavage-activating protein (SCAP) is critical for activation of the
transcription factor SREBP-1. In normal conditions, SREBP-1 is retained in the
endoplasmic reticulum by association with its binding partner, SCAP, which interacts
with resident ER protein INSIG. The absence of sterols promotes the dissociation of
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INSIG from SCAP and allows for SCAP and SREBP-1 to translocate to the Golgi, where
SREBP-1 is cleaved to allow its translocation to the nucleus. However, N-glycosylation
of SCAP is required for this process; when glucose is absent and UDP-GlcNAc levels
are in turn reduced, SCAP is insufficiently N-glycosylated and SREBP-1 is not activated
(Cheng et al., 2015). In this manner, transcriptional control of lipid synthesis depends on
glucose availability and the HBP. Further, since glucose also supplies acetyl-CoA, the
building block for lipid synthesis, this mechanism may prevent activation of lipid
synthesis when insufficient precursor is available. Orthotopic tumor growth is
significantly impaired from glioblastoma cells expressing a mutant form of SCAP that
cannot be N-glycosylated (Cheng et al., 2015). Taken together, glucose availability and
in turn UDP-GlcNAc availability can impact how a cell interprets its nutritional context
through both intracellular O-GlcNAcylation and regulation of membrane protein Nglycosylation.
TCA cycle intermediates: α-ketoglutarate, succinate, and fumarate
TCA cycle intermediates are also critical signaling molecules. For example, α-KG
serves as a substrate for dioxygenase enzymes, including the JMJD histone
demethylases; TET DNA hydroxylases, which facilitate a multi-step DNA demethylation
(Wu and Zhang, 2017); and prolyl hydroxylases that regulate HIFs (Nowicki and Gottlieb,
2015). Succinate and fumarate competitively inhibit these enzymes (Nowicki and
Gottlieb, 2015). The relative concentrations of these metabolites are important in
regulating histone and DNA methylation as well as HIF-1α stabilization.
Aberrant activation of HIF-1α is one mechanism contributing to tumorigenesis
when succinate and fumarate accumulate. Loss-of-function mutations resulting in
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succinate dehydrogenase (SDH) (mutations in SDHA, SDHB, SDHC, or SDHD) or
fumarate hydratase (FH) deficiency result in excess succinate or fumarate, respectively,
and thus inhibition of HIF prolyl hydroxylases. As a consequence of this, SDH or FH
deficiency promotes the stabilization of HIF-1α in normoxic conditions, allowing
expression of HIF target genes such as VEGF and GLUT1 that could promote
angiogenesis and glucose metabolism (Isaacs et al., 2005; Selak et al., 2005). HIF-1α
stabilization in either FH-inhibitor-treated or SDH-deficient cells can be overcome by
adding increasing concentrations of a cell-permeable derivative of α-KG (Isaacs et al.,
2005; MacKenzie et al., 2007), highlighting that the balance between succinate,
fumarate, and α-KG levels determines the activity of HIF prolyl hydroxylases.
The relative concentrations of succinate, fumarate, and α-KG also have broad
effects on histone and DNA methylation in the nucleus and thus gene expression. In
addition to increasing HIF-1α levels, silencing of FH or SDH in cultured cells or in vivo in
the liver inhibits demethylation of histones and DNA (Xiao et al., 2012). Similarly, SDH
mutation in paraganglioma corresponds with increased DNA and histone methylation
and repression of neuroendocrine differentiation genes. In this analysis, patients with the
most hypermethylated tumors, mostly with SDH mutations, had poorer overall and
metastasis-free survival as compared to patients with less methylated tumors.
Interestingly, the only hypermethylated tumor in this study that did not have an SDH
mutation had an inactivating mutation in FH (Letouzé et al., 2013). SDH-deficient
gastrointestinal stromal tumors also show high global DNA methylation levels,
comparable to that observed in IDH mutant glioblastoma (Killian et al., 2013). Recent
work has produced mechanistic insights into roles of fumarate in promoting
tumorigenesis via epigenetic control. FH deficiency in renal cancer corresponds with
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expression of epithelial-to-mesenchymal transition (EMT)-associated genes. This is
mediated through epigenetic silencing of miR-200ba429, a microRNA cluster that
normally functions to restrict expression of genes such as Snai2, Zeb1, and Zeb2 that
coordinate EMT. Fumarate accumulation increases methylation at a regulatory CpG
island, resulting in suppression of miR-200 family microRNAs (Sciacovelli et al., 2016).
Thus, accumulation of metabolites such as succinate and fumarate can drive epigenetic
alterations that promote malignant phenotypes.
Recent evidence indicates that production of (L)-2HG from α-KG catalyzed by
enzymes such as lactate dehydrogenase and malate dehydrogenase may also be a
relevant mechanism of gene regulation in cancer cells (Ye et al., 2018). Acidic pH
promotes these promiscuous reactions, leading to HIF-1α stabilization and increased
histone methylation (Intlekofer et al., 2015, 2017; Oldham et al., 2015). Thus, in addition
to mutations in genes encoding TCA cycle enzymes, microenvironmental conditions can
impact metabolite availability and the activity of α-KG-dependent dioxygenase enzymes.
Concluding remarks
Accumulating evidence supports the concept that metabolites serve as critical
signaling molecules that can impact cancer development and progression. This section
discussed the roles of several key metabolites involved in the regulation of gene
expression and DNA repair and their ties to tumorigenesis. Of course, the pathways and
metabolites highlighted in this section are far from the only relevant mechanisms through
which metabolites signal to the nucleus. NAD+, for example, is also a crucial signaling
metabolite. In addition to its role as a cofactor in metabolic redox reactions, NAD+ is a
substrate of sirtuin deacetylases and PARP enzymes, which regulate diverse cellular
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processes (Cantó et al., 2015; Gupte et al., 2017). NAD+ levels are impacted by
numerous stimuli and conditions, including caloric restriction, aging, exercise, and
circadian oscillations (Rajman et al., 2018), and recent evidence suggests that
compartment-specific NAD+ levels fall within a range that can regulate the reaction rates
of these enzymes (Ryu et al., 2018). Evidence exists for deregulation of NAD+
metabolism in cancer. For example, reduced NAD+ synthesis promotes DNA damage in
early stages of liver cancer development, and supplementation of an NAD+ precursor
suppresses tumorigenesis (Tummala et al., 2014). Lysine acylation, such as
succinylation, malonylation, and crotonylation, is also emerging as a link between
metabolism and gene regulation, though the functions of these modifications are not well
understood (Sabari et al., 2017). Abundance of these modifications on histones closely
correlates with the levels of the corresponding acyl-CoAs (Simithy et al., 2017). How
NAD+ and acyl-CoA availability are altered in cancer and how each impacts protein
modifications, cancer cell phenotypes, and in turn tumorigenesis are exciting areas for
future investigation.
In order to mechanistically understand how metabolites modulate cellular
phenotypes and activities, it will be crucial to further elucidate how specific genes are
regulated in response to changes in the availability of a metabolite. As we have
discussed, two ways that specificity may be achieved are through the coordinated spatial
and temporal control of metabolite production and through metabolite-dependent
regulation of transcription factors (Figure 3). Metabolic state could also potentially modify
cancer phenotypes that arise as a consequence of mutations in or altered expression of
epigenetic enzymes with differential sensitivities to the availability of their metabolite
substrates. Defining compartment-specific interacting partners, mechanisms of nuclear
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trafficking, and roles for dynamic post-translational modification of relevant metabolic
enzymes will aid in further defining the functions of metabolites in gene regulation and
DNA repair.
From a therapeutic standpoint, metabolic regulation of chromatin modification or
transcriptional programs has the potential to expose novel vulnerabilities. Might
metabolic alterations in cancer cells enhance sensitivity to epigenetic therapies? Could
targeting metabolic pathways promote differentiation or suppress EMT and metastasis?
Further, given that acetylation, methylation, and glycosylation can be influenced by
nutrient availability, might a patient’s diet also modulate tumor formation and growth at
least in part via metabolic signaling mechanisms? Could targeting the tumor
microenvironment influence metabolite availability to cancer cells and thereby metabolic
signaling? As discussed, initial evidence in support of each of these possibilities has
emerged, but knowledge of how metabolite-dependent signaling mechanisms might be
exploited for therapeutic benefit is still quite limited and is an important area for
investigation.
In sum, it is now clear that metabolites play key roles in regulating nuclear
processes. Future work will continue to elucidate the mechanisms linking metabolite
availability to gene regulation, with the hope that understanding these mechanisms will
aid in developing new cancer therapies or in identifying cancer prevention strategies.
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Figures

FIGURE 1: Metabolites as Signaling Molecules. In addition to their roles as metabolic
reaction intermediates, metabolites are substrates for post-translational modifications.
Acetyl-CoA (in blue), generated from citrate or acetate, provides acetyl groups for
acetylation. SAM (in red), generated in the methionine cycle as part of one-carbon
metabolism, supplies carbons for methylation. UDP-GlcNAc (in orange) is used for
glycosylation reactions. TCA cycle intermediate α-ketoglutarate (in green) is a required
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substrate for TET DNA hydroxylases and JMJD histone demethylases, while fumarate
and succinate (in green) have inhibitory effects.
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FIGURE 2: Metabolic Signaling Mechanisms Mediate Feedforward Loops in
Control of Nutrient Uptake
(A) In adipocytes, acetyl-CoA generated from glucose both supports fatty acid synthesis
and provides acetyl groups for histone acetylation at genes that promote glucose
metabolism, including GLUT4 (Wellen et al., 2009).
(B) Lung cancer cells with high expression of LAT1 exhibit inc reased SAM and
H3K27Me3 levels. LAT1 expression is increased by activity of the methyltransferase
EZH2, allowing for sustained methionine uptake and SAM production for histone
methylation (Dann et al., 2015).
(C) In breast cancer cells, high levels of O-GlcNAcylation supported by glucose use in
the HBP result in suppressed α-KG levels, which reduces prolyl hydroxylase activity and
promotes HIF-1 stabilization. HIF-1 targets include GLUT1, expression of which
promotes glucose uptake, allowing sustained HBP activity (Ferrer et al., 2014).
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FIGURE 3: Models to Explain How Acetyl-CoA Abundance or Production Can
Regulate Expression of Specific Genes and Histone Acetylation at Distinct Loci.
(A) Post-translational

modification of

nuclear

acetyl-CoA

producers.

Acetyl-CoA-

producing enzymes, such as ACLY, are localized to the nucleus as well as to the
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cytosol. Stimulus-induced post-translational modification of acetyl-CoA producers could
allow the temporal control of acetyl-CoA production within the nucleus. For example,
nuclear ACLY is phosphorylated in response to DNA damage signaling and regulates
H4 acetylation at sites of DNA double-strand breaks to promote DNA repair
by homologous recombination (Sivanand et al., 2017). ACLY utilizes mitochondriaderived citrate as its substrate, and its phosphorylation may allow increased nuclear
capture of citrate for acetyl-CoA production when demand for acetylation increases.
(B) Chromatin recruitment of acetyl-CoA producers. ACSS2 can be recruited to
chromatin and associate with KATs and transcription factors, promoting histone
acetylation at specific loci and gene regulation (Li et al., 2017, Mews et al., 2017).
ACSS2 is crucial for recapturing acetate produced by HDAC reactions to regenerate
acetyl-CoA used by KATs (Bulusu et al., 2017), highlighting the logic behind its emerging
role at chromatin.
(C) Acetyl-CoA-dependent control of transcription factor localization or activity. Nuclear
translocation or activity of specific transcription factors is responsive to acetyl-CoA
abundance, through direct acetylation or through indirect mechanisms, allowing acetylCoA-dependent gene regulation (Galdieri et al., 2016, Lee et al., 2018, Rios Garcia
et al., 2017). Through transcription factor association with KATs, histone acetylation at
target genes is regulated.
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FIGURE

4:

Diagrams

of

One-Carbon

Metabolism

and

the

Hexosamine

Biosynthesis Pathway.
(A) SAM, the substrate for methylation reactions, is generated through the methionine
cycle. Serine also supports SAM production through one-carbon contribution to the
folate cycle to allow regeneration of methionine.
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(B) The HBP branches off of glycolysis at fructose-6-phosphate. In addition to glucose,
the HBP takes inputs from glutamine, acetyl-CoA, and uridine triphosphate as well as
energy input from ATP. The product, UDP-GlcNAc, provides substrate for OGlcNAcylation and N-glycosylation and also is converted to other nucleotide sugars used
in glycosylation, including galactose and CMP-sialic acid.
.
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CHAPTER 2: Metabolic features of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with limited
treatment options. Though survival rates have slowly increased over the last several
years, PDA still has a survival rate of about 11% and is projected to become the leading
cause of cancer deaths by 2030 (Rahib et al., 2014). A major reason for this is that PDA
can develop for years without manifestation of any symptoms, leading to detection when
the cancer is already in late stage and difficult to treat. Further, PDA tumor cells readily
metastasize (Rhim et al., 2012), and thus by the time PDA is detected it has already
spread throughout the body. Improved understanding of the biology of PDA development
and progression is critical to enhancing our ability to diagnose and treat this disease.
There are several hallmark features of PDA that contribute to its difficulty to treat.
About 80% of PDA are driven by mutations in RAS, and of those about 90% are driven
by KRAS mutation (Mukhopadhyay et al., 2021). RAS proteins are membraneassociated small GTPases that act downstream of growth factor receptors to promote
cell growth and proliferation. Mutant forms of RAS are constitutively active and thus
contribute to tumor growth, which is exacerbated by other mutations such as the loss of
tumor suppressor p53. However, RAS proteins are also critical to normal cell function
and targeting RAS proteins with pharmacological inhibitors without ubiquitous toxicity is
challenging. PDA tumors are also characterized by a desmoplastic reaction that
generates a dense stromal compartment in the tumor microenvironment (Chu et al.,
2007; Jacobetz et al., 2013; Provenzano et al., 2012). Much of the tumor mass is
actually comprised of extracellular matrix (ECM) and other cell types such as cancerassociated fibroblasts (CAFs) and immune cells. While the stromal compartment has
been shown to constrain tumor growth (Özdemir et al., 2014; Rhim, Oberstein, Thomas
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et al., 2014) the density of this material surrounding the tumor cells can also prevent
pharmacological agents from reaching the tumor. Further, stromal cells can promote
tumor growth through metabolite and signaling crosstalk, which will be discussed later in
this section.
While these characteristics hinder the efficacy of existing therapeutics against
PDA, they also create unique metabolic attributes of the tumor that could be exploited as
new treatments are developed. This section will discuss three major areas of metabolic
alteration in PDA: tumor cell-intrinsic metabolic changes driven by mutant KRAS,
recycling and scavenging of biosynthetic materials, and crosstalk between cell types
within the tumor microenvironment.
KRAS mutation drives metabolic changes in PDA tumor cells

Many tumor cell-intrinsic metabolic changes in PDA are dependent on
expression of mutant KRAS, which occurs in the vast majority of PDA tumors. Perhaps
the most salient of these is the upregulation of glucose transporter GLUT1 and
increased expression of glycolysis-related genes (Gaglio et al., 2011; Ying et al., 2012).
While aerobic glycolysis, or the Warburg effect, is observed in a wide array of cancer
types (Vander Heiden et al., 2009), it was shown using a mouse model of PDA with
inducible expression of mutant KRAS that increased glycolytic flux and expression of key
glycolytic enzymes such as HK2 were dependent specifically on mutant KRAS
expression(Ying et al., 2012). Further, KRAS drives expression of genes and proteins
involved in two other key biosynthetic pathways that branch off of glycolysis, the nonoxidative arm of the pentose phosphate pathway and the hexosamine biosynthesis
pathway (HBP).
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While targeting glycolysis is less likely to be a successful therapeutic strategy
because this pathway is used by normal cells to maintain homeostasis, the fact that PDA
cells upregulate these other glucose-dependent pathways could expose new
vulnerabilities. The pentose phosphate pathway generates key units for nucleotide
synthesis. Expression of a key pentose phosphate pathway enzyme, ribose-5phosphate-isomerase (RPIA), is regulated by MYC downstream of KRAS. Knockdown of
RPIA limits cell growth and increases cell death in PDA cell lines in vitro, and this effect
can be rescued by nucleotide supplementation, indicating that the antiproliferative
effects are due to insufficient nucleotide metabolites (Santana-Codina et al., 2018).
Pharmacological inhibition of another enzyme in pyrimidine synthesis, dihydroorotate
dehydrogenase (DHODH), limits initial subcutaneous PDA tumor growth in vivo, but
ultimately the tumors are able to grow similar to vehicle treated tumors, indicating that
compensatory mechanisms are likely activated (Santana-Codina et al., 2018). It is
possible that salvage and recycling pathways, discussed in the next section, are
responsible for overcoming inhibition of different aspects of nucleotide synthesis.
As described in the previous chapter, the HBP generates uridine diphosphate Nacetylglucosamine (UDP-GlcNAc), a key substrate for glycosylation in the cell. The HBP
is upregulated in a number of cancers in addition to PDA (Ferrer et al., 2014), though the
reasons for this are not well understood. Recent studies have taken different approaches
to targeting this pathway. One is use of the inhibitor 6-diazo-5-oxo-L-norleucine (DON),
which inhibits the rate-limiting enzyme of the HBP, glutamine-f6p aminotransferase
(GFPT1, also called GFAT1). Treatment with this inhibitor reduced tumor cell production
of hyaluronic acid (HA), allowing improved infiltration of anti-tumor T-cells and sensitizing
tumors to anti-PD-L1 therapy (Sharma et al., 2020). A new inhibitor targeting
phosphoacetylglucosamine mutase (PGM3), a later enzyme in the pathway, has been
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shown to limit tumor growth in gemcitabine-resistant PDA patient-derived xenografts
(Ricciardiello et al., 2020). This strategy is particularly promising because it targets both
de novo HBP and hexosamine salvage, which generates UDP-GlcNAc from free
GlcNAc. This type of nutrient recycling is another key feature of PDA, discussed next.
Nutrient recycling and scavenging
Because the PDA microenvironment is highly desmoplastic and poorly
vascularized, nutrient distribution throughout the tumor is uneven and tumor cells employ
strategies to obtain the metabolites they need. One method is autophagy, which is the
lysosomal breakdown of a cell’s own material. In normal tissue autophagy is generally
only activated when a cell needs to survive a period of stress, but in several cancer
types it is highly active, including in PDA (Yang et al., 2011). In KRAS-driven mouse
models of PDA, ablation of autophagy machinery components limits tumor progression
(Rosenfeldt et al., 2013; Yang et al., 2014). From a metabolic standpoint, autophagy can
supply the tumor cell with glycolytic and TCA cycle intermediates, nucleotides, and
amino acids (Guo et al., 2011, 2016a; Lock et al., 2011; Perera et al., 2015). Recently, a
non-metabolic role for autophagy was established. Through autophagy, PDA cells
selectively downregulate MHC-I presentation at the cell surface, which allows them to
evade the immune system. Inhibition of autophagy then can restore MHC-I at the
surface and increase anti-tumor T-cell response (Yamamoto et al., 2020). Thus,
autophagy may serve both metabolic and non-metabolic roles in PDA.
Another metabolite recycling mechanism is macropinocytosis, the non-selective
uptake of extracellular fluid and any material contained in that fluid. Oncogenic RAS
signaling triggers actin remodeling through the Rac pathway in a PI3K-dependent
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manner, which promotes membrane ruffling and the engulfment of extracellular material
(Amyere et al., 2000; Bar-Sagi and Feramisco, 1986; Walsh and Bar-Sagi, 2001).
Because PDA tumors are highly desmoplastic and poorly vascularized, nutrient
distribution throughout the tumor is uneven and macropinocytosis allows cells to
scavenge material from their environment. A key function of macropinocytosis is to
supply amino acids through uptake of extracellular protein (Commisso et al., 2013;
Kamphorst et al., 2015). PDA cells proliferate slowly in vitro in glutamine-deprived
conditions, but supplementation of low glutamine media with albumin could overcome
this proliferation defect by replenishing cellular glutamine and α-ketoglutarate levels.
Further, macropinocytosis inhibition limits subcutaneous PDA tumor growth in
immunodeficient mice (Commisso et al., 2013). However, because macropincytosis is
nonspecific in nature, it is possible that macropinocytosis is supplying the cell with a
variety of material available in the tumor microenvironment, such as extracellular matrix
(ECM) components and debris from necrotic cells.
Metabolic crosstalk in the tumor microenvironment
Tumor cells themselves make up a small proportion of the cells in a PDA tumor.
Other cell types in the microenvironment, also called the stroma, include pancreatic
stellate cells (PSCs), cancer-associated fibroblasts, and a range of immune cell types.
Growth factor and cytokine signaling between stromal cells and tumor cells has been
shown to impact tumor growth and development (Mcallister et al., 2014; Pylayeva-Gupta
et al., 2016), but metabolic crosstalk between these cells can also produce such effects.
For example, activated pancreatic stellate cells (PSCs) produce and secrete
lysophosphatidylcholines (LPCs), a specific type of lipid, that are metabolized by the
secreted enzyme autotaxin to lysophosphatidic acid (LPA). LPA drives AKT signaling,
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proliferation, and migration in tumor cells PDA. Interestingly, both activated PSCs and
tumor cells produce autotaxin and thus both contribute to driving this signaling axis
(Auciello et al., 2019). Tumor cells can incorporate LPCs into membrane components,
indicating a biosynthetic role for these secreted metabolites as well (Auciello et al.,
2019). In addition to lipids, CAFs produce high amounts of collagen, which is rich in the
amino acid proline. When cultured in nutrient deprived conditions, PDA cells take up
collagen via macropinocytosis and utilize the proline contained therein to fuel the TCA
cycle. Deletion of proline oxidase in PDA cells injected subcutaneously into
immunodeficient mice limited tumor growth, indicating that collagen-derived protein is
important for sustaining tumor cell metabolism (Olivares et al., 2017). Communication
between stromal cells and tumor cells can also run the opposite direction, with tumor
cells impacting stromal cell metabolism. Conditioned media from PDA cells induces
autophagy in PSCs in vitro, which suggests this effect is achieved through a secreted
factor. This effect coincides with PSC secretion of alanine in an autophagy-dependent
manner; the secreted alanine is taken up by tumor cells and used in the TCA cycle,
freeing up glucose carbons for use in serine and glycine synthesis. In a syngeneic
orthotopic tumor model, co-injection of murine PSCs with tumor cells improved tumor
take. Knockdown of autophagy machinery components in the PSCs eliminated this
effect, indicating a role for this autophagy-driven alanine secretion in tumor initiation
(Sousa et al., 2016).
Another consideration related to metabolic crosstalk is competition for nutrients
between various stromal cell types and tumor cells, especially when considering the
immune compartment. It is well established that activated, anti-tumor immune cells have
specific metabolic phenotypes and thus have certain metabolic requirements (Araujo et
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al., 2017; Berod et al., 2014; Ma et al., 2019; Macintyre et al., 2014). A recent study in
kidney tumors determined that inflammatory myeloid cells consume the most glucose
per-cell in the tumor microenvironment, while tumor cells were more likely to consume
glutamine and fatty acids as fuel sources (Reinfeld et al., 2021). Similar studies in PDA
could provide insight into ways to improve responses to immunotherapy.
Concluding remarks: How are KRAS-driven metabolic changes sustained in the
harsh tumor microenvironment?
PDA is characterized by cell-intrinsic metabolic changes, many driven by
oncogenic KRAS, and metabolic features guided by interactions within the tumor
microenvironment. While the signaling mechanisms behind these phenotypes are
complex, continuing to understand the uniqueness of PDA metabolism could lead to
improvement of existing therapeutic strategies and identification of novel therapeutic
targets specific to the disease.
As described in this section, mutant KRAS expression increases flux into the
HBP, which generates UDP-GlcNAc, a key substrate in glycosylation. This pathway
requires glucose, glutamine, acetyl-CoA, ATP, and uridine triphosphate (UTP) and is
often referred to as a nutrient sensing pathway. However, also described in this section
is the dense stroma that comprises the tumor microenvironment and leads to uneven
nutrient distribution throughout the tumor, causing tumor cells to leverage adaptive
nutrient acquisition strategies such as macropinocytosis. Given that the HBP
incorporates such a diverse range of substrates, it is surprising that this pathway would
be upregulated in nutrient poor regions of the tumor. In this work, we will probe this
pathway further to determine how UDP-GlcNAc synthesis is sustained even when
nutrients are not available.
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Figures

FIGURE 1: How is UDP-GlcNAc synthesis sustained when HBP substrates are not
available? The HBP is upregulated in PDA in a KRAS-dependent manner. However,
PDA tumors are characterized by a dense stromal microenvironment and variable
nutrient distribution. This work will examine how KRAS-dependent metabolic changes
such as upregulation of the HBP are maintained in nutrient-poor regions of the tumor.
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CHAPTER 3: Glutamine deprivation triggers NAGK-dependent hexosamine
salvage

Introduction
Altered glycosylation is frequently observed in malignancies, impacting tumor
growth as well as immune and therapeutic responses (Akella et al., 2019; Mereiter et al.,
2019). Several types of glycosylation, including O-GlcNAcylation and N-linked
glycosylation, are dependent on the glycosyl

donor uridine diphosphate N-

acetylglucosamine (UDP-GlcNAc), which is synthesized by the hexosamine biosynthesis
pathway (HBP). The HBP branches off from glycolysis with the transfer of glutamine’s
amido group to fructose-6-phosphate (F-6-P) to generate glucosamine-6-phosphate
(GlcN-6-P), mediated by the rate limiting enzyme glutamine—fructose-6-phosphate
transaminase (GFPT1/2). The pathway further requires acetyl-CoA, ATP, and uridine
triphosphate (UTP) to ultimately generate UDP-GlcNAc. O-GlcNAcylation, the addition of
a single N-acetylglucosamine (GlcNAc) moiety onto a serine or threonine residue of
intracellular proteins, is upregulated in multiple cancers (Akella, et al., 2019). Targeting
O-GlcNAcylation suppresses the growth of breast, prostate, and colon cancer tumors
(Caldwell et al., 2010; Ferrer et al., 2017; Gu et al., 2010; Guo et al., 2017; Lynch et al.,
2012). Similarly, certain N-glycan structures (e.g., tetra-antennary N-glycans) are highly
sensitive to HBP flux and are upregulated in malignant tissue, and targeting the relevant
glycan remodeling enzymes can limit tumor growth and metastasis in vivo (Granovsky et
al., 2000; Li et al., 2008; Zhou et al., 2011). Thus, understanding the regulation of the
HBP in cancer could point towards novel therapeutic strategies.
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Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with a 5-year
survival rate of 9% and a rising number of annual deaths (Rahib et al., 2014) (ACS
Cancer Facts and Figures 2019, NIH SEER report 2019). Mutations in KRAS occur in
nearly all cases of human PDA and drive extensive metabolic reprogramming in cancer
cells. Enhanced flux into the HBP was identified as a primary metabolic feature mediated
by mutant KRAS in PDA cells (Ying et al., 2012). Hypoxia, a salient characteristic of the
tumor microenvironment (Lyssiotis and Kimmelman, 2017), was shown to further
promote expression of glycolysis and HBP genes in pancreatic cancer cells(Guillaumond
et al., 2013). Notably, the glutamine analog 6-diazo-5-oxo-L-norleucine (DON), which
inhibits the HBP, suppressed PDA metastasis and sensitized PDA tumors to anti-PD-L1
therapy (Sharma et al., 2020). DON has also been reported to sensitize PDA cells to the
chemotherapeutic gemcitabine in vitro (Chen et al., 2017b). Additionally, a recently
developed inhibitor targeting the HBP enzyme phosphoacetylglucosamine mutase 3
(PGM3) enhances gemcitabine-mediated reduction of xenograft tumor growth in vivo
(Ricciardiello et al., 2020). Thus, the HBP may represent a therapeutic target in PDA,
although the regulation of UDP-GlcNAc synthesis and the optimal strategies to target
this pathway for therapeutic benefit in PDA remain poorly understood.
An outstanding question is the impact of the tumor microenvironment on UDPGlcNAc synthesis. The HBP has been proposed as a nutrient-sensing pathway since its
rate-limiting step, mediated by GFPT1/2, requires both glutamine and the glycolytic
intermediate fructose-6-phosphate (Denzel and Antebi, 2015). In hematopoietic cells,
glucose deprivation limits UDP-GlcNAc levels and dramatically reduces levels of the Nglycoprotein IL3Rα

at the plasma membrane in a manner dependent on the HBP

(Wellen et al., 2010). Similarly, O-GlcNAcylation of certain nuclear-cytosolic proteins,
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including cancer-relevant proteins such as Myc and Snail, has been demonstrated to be
nutrient sensitive, impacting protein stability or function (Housley et al., 2008; Park et al.,
2010; Swamy et al., 2016). Yet, the PDA tumor microenvironment is thought to be
particularly nutrient poor, owing to its characteristic dense stroma (Halbrook and
Lyssiotis, 2017). This raises the question of how nutrient deprivation impacts the
synthesis of UDP-GlcNAc and its utilization for glycosylation. Understanding how PDA
cells regulate these processes under nutrient limitation could identify therapeutic
vulnerabilities. In this study, we investigated the impact of nutrient deprivation on the
HBP and glycosylation in PDA cells, identifying a key role for hexosamine salvage
through the enzyme N-acetylglucosamine kinase (NAGK) in PDA tumor growth.
Results

Tetra-antennary N-glycans and O-GlcNAcylation are minimally impacted by
nutrient limitation in pancreatic cancer cells

To examine the effects of nutrient deprivation on glycosylation in PDA cells, we
cultured the cells in low glucose or low glutamine conditions and examined O-GlcNAc
levels, as well as cell surface phytohemagglutinin-L (L-PHA) binding, a readout of Nacetylglucosaminyltransferase 5 (MGAT5)-mediated cell surface N-glycans (Fig S1A,B),
which are highly sensitive to UDP-GlcNAc availability (Lau et al., 2007). We focused on
glucose and glutamine because of their requirement to initiate the HBP (Fig. 1A). As a
positive control, we examined HCT-116 and SW480 colon cancer cells, previously
documented to have glucose-responsive O-GlcNAcylation (Park et al., 2010;
Steenackers et al., 2016), which we also confirmed in HCT-116 cells (Fig. 1B). Indeed,
LPHA binding was suppressed by glucose restriction in SW480 cells and by glutamine
restriction in both colon cancer cell lines (Fig. 1C). To test whether glycans were
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sensitive to nutrient restriction in pancreatic cancer cells, we examined LPHA binding
and O-GlcNAc levels under nutrient deprivation conditions in a panel of human PDA cell
lines, including PANC-1, MIA PaCa-2, AsPC-1, and HPAC. Across these cell lines, no
consistent changes in L-PHA binding were observed under glucose or glutamine
limitation (Fig. 1D, E; Fig. S1C). We also examined L-PHA binding in PDA cells under
oxygen- or serum-deprived conditions and observed again that levels were overall
maintained (Figure S1D, E). O-GlcNAcylation was minimally altered by culture in low
glutamine and exhibited variable changes in response to glucose limitation (Fig. 1F),
consistent with stress-induced regulation of this modification (Taylor et al., 2008). Thus,
under a variety of nutrient stress conditions, neither L-PHA binding nor O-GlcNAcylation
were consistently suppressed in pancreatic cancer cell lines. Glutamine restriction in
particular had remarkably little impact on O-GlcNAcylation and L-PHA binding, raising
the question of how glycosyl donors are generated during nutrient limitation.
Pancreatic cancer cells generate UDP-GlcNAc through salvage

Since UDP-GlcNAc is synthesized de novo through the HBP, we next asked
whether abundance of HBP metabolites is impacted by nutrient limitation. We measured
HBP metabolites after glucose or glutamine restriction using HPLC-MS (Guo et al.,
2016). In low glutamine conditions, GlcN-6-P levels were potently decreased relative to 4
mM glutamine in PANC-1 cells, while UDP-GlcNAc abundance was maintained (Fig.
2A). In MIA PaCa-2 cells, UDP-GlcNAc abundance actually increased upon glutamine
restriction (Fig S2.1A).

These data indicate that UDP-GlcNAc might be generated

through mechanisms other than de novo synthesis. Glycolytic intermediates were
minimally impacted by low glutamine conditions, and TCA cycle intermediates such as αKG and malate decreased as expected (Fig. 2A, Fig. S2.1A). In contrast to glutamine
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restriction, UDP-GlcNAc was not maintained in 5 mM or 0.1 mM glucose conditions (Fig.
S2.1B), suggesting that glutamine limitation specifically may trigger an adaptive
response to sustain UDP-GlcNAc pools.
We sought to understand how UDP-GlcNAc pools are sustained during
glutamine restriction. In addition to de novo synthesis of UDP-GlcNAc via the HBP, free
GlcNAc in the cell can also be phosphorylated via N-acetylglucosamine kinase (NAGK)
to produce GlcNAc-P and then regenerate UDP-GlcNAc (Fig. 2B). However, NAGK’s
roles in physiology and cancer biology have been minimally studied. Thus, to investigate
the possibility that UDP-GlcNAc is generated through mechanisms other than its
synthesis from glucose, we designed an isotope labeling strategy to determine the
fraction of the glucosamine ring that is synthesized de novo. Since multiple components
of UDP-GlcNAc [glucosamine ring, acetyl group, uridine (both the uracil nucleobase and
the ribose ring)] can be synthesized from glucose, UDP-GlcNAc isotopologues up to
M+16 can be generated from glucose (Moseley et al., 2011) (Fig. 2C). In order to
measure the glucose carbon incorporated into GlcNAc-P and UDP-GlcNAc via the HBP,
all isotopologues containing a fully labeled glucosamine ring are added together (%
labeled GlcN equals sum of M+6, M+8, M+11, and M+13 for UDP-GlcNAc and sum of
M+6 and M+8 for GlcNAc-P) (Fig. 2C). After 48 hours of glutamine restriction, cells were
incubated with fresh low glutamine medium containing [U-13C]-glucose to track the
incorporation of glucose carbons into hexosamine intermediates. Across multiple PDA
cell lines, the fractional labeling of the glucosamine ring in both GlcNAc-P and UDPGlcNAc pools was significantly suppressed by glutamine restriction, indicating
decreased de novo synthesis in low glutamine conditions (Fig. 2D, Fig. S2.1C-E).
Notably, labeling into the ribose component of UDP-GlcNAc was also suppressed.
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Consistently, incorporation of

13

C glucose into uridine triphosphate (UTP) was

suppressed upon glutamine restriction (Fig. S2.2A), even though UTP levels were
maintained (Fig. 2A, Fig. S2.1A), suggesting a role for nucleoside salvage in maintaining
nucleotide pool. This is consistent with previous reports demonstrating that autophagy is
a source of nucleotides in amino acid deprived conditions (Guo et al., 2011; Wyant et al.,
2018). Indeed, silencing of either of the uridine salvage enzymes uridine kinase 1 or 2
(UCK1/2) resulted in decreased UDP, UTP, and UDP-GlcNAc levels (Fig. S2.2B, C).
We noted that GlcNAc-P and UDP-GlcNAc pools labeled from glucose with
similar but not identical kinetics. We therefore considered whether other pathways may
also have minor contributions to glucose-dependent UDP-GlcNAc labeling. The Leloir
pathway enzyme GALE interconverts UDP-GlcNAc and UDP-GalNAc, but

13

C

incorporation into the glucosamine ring of UDP-GlcNAc abundance was not suppressed
upon GALE silencing (fig S2.2D). Thus, GALE does not facilitate an alternate route to
UDP-GlcNAc synthesis from glucose. Sialic acid biosynthesis also branches off from
UDP-GlcNAc, initiated by the enzyme UDP-GlcNAc-2-epimerase/ManAc kinase (GNE)
which produces ManNAc and UDP. This reaction is irreversible, and as expected, GNE
silencing also did not suppress UDP-GlcNAc synthesis from glucose (Fig. S2.2D). M+6
UDP-GlcNAc could also be generated in principle through 6 carbons in UTP becoming
labeled (e.g. 5 carbons in ribose and 1 carbon in uracil); however this is minimally
observed in UTP labeling (Fig. S2.2A). The slight differences in timing of GlcNAc-P and
UDP-GlcNAc labeling may thus either reflect an unknown pathway or technical
limitations in metabolite detection, as UDP-GlcNAc is more abundant than GlcNAc-P.
Nevertheless, the data clearly indicate that UDP-GlcNAc abundance is maintained under
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glutamine restriction (Fig. 2A, Fig. S2.1A) despite reduced de novo hexosamine
synthesis from glucose (Fig. 2D).
As mentioned earlier, UDP-GlcNAc can also be generated via phosphorylation of
free GlcNAc by NAGK generating GlcNAc-6-P (Fig. 2B). Sources of GlcNAc in the cell
may

include

removal

of

O-GlcNAc

protein

modifications

or

breakdown

of

glycoconjugates and extracellular matrix components. Yet, the significance of NAGK to
maintenance of UDP-GlcNAc pools has been little studied, and the proportion of UDPGlcNAc generated via the NAGK-dependent salvage pathway is unknown. NAGK mRNA
expression increased in PDA cell lines in low glutamine conditions, and in some cell
lines also in low glucose (Fig. S2.3A, B). GFPT1 expression was induced in both low
glucose conditions, consistent with a prior report (Moloughney et al., 2016), and in low
glutamine conditions (Fig. S2.3A), even though de novo synthesis is suppressed when
glutamine is limited. Protein levels of NAGK did not increase in concordance with mRNA,
however, though a mobility shift potentially indicative of post-translational modification
was apparent under nutrient restriction (Fig S2.3C). Removal of phosphatase inhibitor
from the sample buffer prevented the mobility shift for NAGK, suggesting NAGK is
phosphorylated in low glutamine conditions, but added phosphatase did not produce any
additional effect in either whole cell lysate or immunoprecipitated NAGK (Fig. S2.3C, D).
Thus, further work is necessary to characterize post-translational modification of NAGK
and its function. These data indicate that under low glutamine conditions, de novo
hexosamine synthesis from glucose is reduced, free GlcNAc abundance increases, and
the salvage enzyme NAGK is subject to regulation.

41

NAGK deficiency reveals inherent flexibility between hexosamine synthesis and
salvage

These findings prompted us to investigate the role of NAGK in UDP-GlcNAc
synthesis in PDA cells. We functionally examined the role of NAGK in PDA cell lines by
using CRISPR-Cas9 gene editing to generate NAGK knockout (KO) PANC-1 and
MiaPaCa-2 cell lines (Fig. S3.1A, B). N-[1,2-13C2]acetyl-D-glucosamine (13C GlcNAc)
was efficiently salvaged in control cells, and this was suppressed by NAGK deletion, as
evidenced by reduced fractional labeling of GlcNAc-P and UDP-GlcNAc (Fig. 3A). As we
did not observe any residual protein expression by western, we hypothesized that Nacetylgalactosamine kinase (GALK2) might be responsible for the remaining GlcNAc
salvage in the absence of NAGK. Indeed, knockdown of GALK2 further suppressed
incorporation of 13C GlcNAc into GlcNAc-P and UDP-GlcNAc (Fig. S3.1C)
We hypothesized that knockout cells would conduct increased de novo UDPGlcNAc synthesis. To test this, we incubated cells with [U-13C]-glucose and examined
incorporation into GlcNAc-P and UDP-GlcNAc. Indeed, we observed increased fractional
labeling of hexosamine intermediates including UDP-GlcNAc and GlcNAc-P from
glucose in the absence of NAGK (Fig. 3B-C; Fig. S3.1D-E).

This effect was also

observed with knockdown of NAGK by shRNA, though to a lesser extent (Fig. S3.2B-C).
Importantly, incorporation of glucose into F-6-P did not change (Fig. 3B) and the
proportion of UDP-GlcNAc containing an m+5 ribose ring was unchanged in knockout
cells (Fig. 3C), indicating that NAGK specifically impacts glucose flux into the HBP and
not into other glucose-utilizing pathways. Thus, PDA cells exhibit flexibility in UDPGlcNAc production, via de novo synthesis or salvage. In low glutamine conditions, in
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which substrate for de novo synthesis is limited and NAGK is upregulated, HBP flux is
limited and cells are able to maintain UDP-GlcNAc levels through GlcNAc salvage.
However, when NAGK is deleted and GlcNAc salvage is ablated, cells are readily able to
increase flux of glucose into the HBP provided that substrate is available.
We next assessed changes in the levels of hexosamine intermediates in high
and low glutamine conditions in control and clonal NAGK KO cell lines. In 4 mM
glutamine, changes in metabolite levels were specific to each cell type. In PANC-1 KO
cells, F-6-P abundance was not changed on average across clones, but GlcN-P
increased significantly, consistent with increased de novo synthesis in the absence of
NAGK (Fig. 3D). GlcNAc-P was reduced on average in KO cells, consistent with NAGK
loss, and UDP-GlcNAc levels were maintained (Fig. 3D). In MIA PaCa-2 cells, in
contrast with PANC-1 cells, F-6-P increased in KO cells while GlcN-P levels remained
the same (Fig. S3.2A). GlcNAc-P was more markedly decreased in KO MIA PaCa-2
cells than in PANC-1 cells, and again UDP-GlcNAc levels remained constant (Fig.
S3.2A). We next measured HBP metabolites in 0.05 mM glutamine, w here we expected
NAGK would play a more significant role in UDP-GlcNAc generation. We were only able
to measure metabolites accurately in PANC-1 KO cells because MIA PaCa-2 NAGK KO
cells began to die quickly in low glutamine, which will be discussed furthe r in the next
section. As in 4 mM glutamine, F-6-P abundance did not change overall in KO cells in
0.05 mM glutamine (Fig. 3D). GlcN-P decreased in both control and KO cells, likely due
to the unavailability of glutamine as a substrate (Fig. 3D). GlcNAc-P levels again
decreased overall (Fig. 3D). While UDP-GlcNAc was maintained in KO cells relative to
the 4 mM glutamine condition, UDP-GlcNAc levels were decreased on average in KO
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cells compared to control cells. As NAGK deletion did not necessarily limit UDP-GlcNAc
levels, we next sought to examine other functional effects of NAGK loss.
NAGK knockout limits tumor growth in vivo

To test the role of NAGK in cell proliferation, we first monitored growth of NAGK
KO cells compared to controls in 2D and 3D culture in 4 mM glutamine, finding minimal
differences (Fig. 4A, Fig. S4A). We hypothesized that NAGK KO cell proliferation would
be impaired in 0.05 mM glutamine, where de novo UDP-GlcNAc synthesis is typically
suppressed. Indeed, MIA PaCa-2 KO cells proliferated less and died more quickly in
0.05 mM glutamine than did control cells (Fig. 4A). PANC-1 KO cells did not show this
effect (Fig. 4A), but we hypothesized that NAGK loss might have a stronger effect on
proliferation in these cells in vivo where tumor growth can be constrained by nutrient
availability. To gain initial insight into whether NAGK is likely to play a functional role in
PDA progression in vivo, we queried publicly available datasets. From analysis of
publicly available microarray data (Pei et al., 2009) and gene expression data from the
Cancer Genome Atlas (TCGA), we indeed found NAGK expression to be increased in
tumor tissue relative to adjacent normal regions of the pancreas (Fig. 4B, Fig. S4B).
GFPT1 expression was also increased in tumor tissue (Fig. 4B, Fig. S4B), consistent
with its regulation by mutant KRAS (Ying et al., 2012). Two other HBP genes, PGM3 and
UAP1, did not show significantly increased expression in PDA tumors in these datasets
(Fig. 4B, Fig. S4B). We then studied the role of NAGK in tumor growth in vivo by
injecting NAGK CRISPR KO cells into the flank of NCr nude mice (Fig. 4C). Final tumor
volume and weight were markedly reduced in the absence of NAGK (Fig. 4E, F). Of
note, initial tumor growth was comparable between control and KO cells, but the NAGK
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knockout tumors either stopped growing or shrank while control tumors continued to
grow larger (Fig. S4C), consistent with the notion that NAGK becomes more important
as the tumors outgrow their original nutrient supply and become more dependent on
scavenging and recycling. Interestingly, while KO cell tumor growth was dramatically
reduced, KO tumor samples showed increased L-PHA binding (Fig. S4D), indicative of
MGAT5-modified complex N-glycans (Fig. S1A). While NAGK knockout cells display no
protein expression of NAGK in vitro (Fig. S3.1B), NAGK knockout tumors showed some
expression of NAGK, possibly from other cell types (Fig. 4C). Thus, this increase in
LPHA could also indicate infiltration of other cell types into the tumor, or differential
crosstalk between tumor cells and other cells in the microenvironment that lead to LPHA
differences. Understanding these effects will require further characterization of these
tumor samples. Regardless, combined, these data indicate that NAGK-mediated
hexosamine salvage supports tumor growth in vivo.
Materials and methods
Cell culture
Cells were cultured in DMEM high glucose (Gibco, 11965084) with 10% calf serum
(Gemini GemCell U.S. Origin Super Calf Serum, 100-510), unless otherwise noted.
Glucose- or glutamine-restricted media was prepared using glucose, glutamine, and
phenol red free DMEM (Gibco, A1443001) supplemented with glucose (Sigma-Aldrich,
G8769), glutamine (Gibco, 25030081), and dialyzed fetal bovine serum (Gemini, 100108). For all glutamine restriction experiments, cells were plated 2-3x more densely for
the nutrient restricted condition samples to achieve similar confluency at the experiment
endpoint. 1% oxygen levels were achieved by culturing cells in a Whitley H35
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Hypoxystation (Don Whitley Scientific). ATCC names and numbers for the cell lines used
in this study are: MIA PaCa-2 (ATCC# CRL-1420), Panc-1 (ATCC# CRL-1469), HPAC
(ATCC# CRL-2119), AsPC-1 (ATCC# CRL-1682), BxPC-3 (ATCC# CRL-1687), HCT
116 (ATCC# CCL-247), and SW480 (ATCC# CCL-228). All cells were routinely tested
for mycoplasma and authenticated by short tandem repeat (STR) profiling using the
GenePrint 10 System (Promega, B9510).
Generation of CRISPR cell lines
sgRNA sequences targeting NAGK or Mgat5 from the Brunello and Brie libraries
(Doench et al., 2016) were cloned into the lentiCRISPRv2 vector (Sanjana, Shalem et
al., 2014). Lentivirus was produced in 293T cells according to standard protocol. Cells
were then infected with the CRISPR lentivirus and selected with puromycin. Cells were
plated at very low density into 96 well plates to establish colonies generated from single
cell clones. Mgat5 gene disruption was validated by qPCR and L-PHA binding. NAGK
gene disruption was validated by qPCR and western blot. Four NAGK knockout clonal
cell lines established from two different sgRNAs were chosen for use in the study.
Please see table at end of chapter for primer sequences of guides used.
Western blotting
For protein extraction from cells, cells were kept on ice and washed three times with
PBS, then scraped into PBS and spun down at 200g for 5 minutes. The cell pellet was
resuspended in 50-100

L RIPA buffer [1% NP-40, 0.5% deoxycholate, 0.1% SDS, 150

mM NaCl, 50 mM Tris plus protease inhibitor cocktail (Sigma-Aldrich, P8340) and
phosSTOP (Sigma-Aldrich, 04906845001)] and lysis was allowed to continue on ice for
10 minutes. Cells were sonicated with a Fisherbrand Model 120 Sonic Dismembrator
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(Fisher Scientific, FB120A110) for three pulses of 20 seconds each at 20% amplitude.
Cell lysate was spun down at 15,000g for 10 minutes at 4 oC and supernatant was
transferred to a new tube. For protein extraction from tissue, the sample was
resuspended in 500

L RIPA buffer and homogenized using a TissueLyser (Qiagen,

85210) twice for 30s at 20 Hz. Following incubation on ice for 10 minutes the same
procedure was followed as for cells. For both cells and tissue, lysate samples were
stored at -80oC until analysis by immunoblot. All blots were developed using a LI-COR
Odyssey CLx system. Antibodies used in this study were: O-GlcNAc CTD110.6 (Cell
Signaling 9875S), tubulin (Sigma T6199), HSP60 (Cell Signaling 12165S), and NAGK
(Atlas Antibodies, HPA035207).
RT-qPCR
For RNA extraction from cells, cells were put on ice, washed with PBS, and scraped into
PBS. Samples were then spun down at 200g for 5 minutes and resuspended in 100

L

Trizol (Life Technologies). For RNA extraction from tissue, samples were resuspended
in 500

L Trizol and homogenized using a TissueLyser twice for 30s at 20 Hz. For both

cells and tissue, RNA was extracted following the Trizol manufacturer protocol. cDNA
was prepared using high-capacity RNA-to-cDNA master mix (Applied Biosystems,
4368814) according to kit instructions. cDNA was diluted 1:20 and amplified with
PowerUp SYBR Green Master Mix (Applied Biosystems, A25778) using a ViiA-7 RealTime PCR system. Fold change in expression was calculated by the ΔΔCt method using
HPRT as a control. Please see table at end of chapter for primer sequences.
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Lectin binding assay
Cells were put on ice, washed with PBS and then scraped into PBS. Samples were then
spun down at 200g for 5 minutes and resuspended in 3% BSA with fluorophoreconjugated lectin added 1:1000. Samples were covered and incubated on ice for 30
minutes at room temperature, then spun down and resuspended in PBS before analysis
with an Attune NxT Flow Cytometer (Thermo Fisher Scientific). Data was further
analyzed using FlowJo 8.7.
Metabolite quantitation and labeling
For all metabolite quantitation experiments, each sample was collected from a 10 cm
sub-confluent plate of cells. To achieve similar confluency and protein content at the
experiment endpoint, cells were initially plated more densely for the nutrient deprived
samples than for the nutrient replete samples. For low glutamine experiments, PANC-1
cells were plated 3x105 for 4 mM glutamine samples and 5.5x105 for 0.05 mM samples.
MIA PaCa-2 cells were plated 3x105 for 4 mM samples and 1.2x106 for 0.05 mM
samples.
Samples were prepared according to Guo et al. (Guo et al., 2016). Briefly, cells were put
on ice and washed 3x with PBS. Then, 1 mL of ice cold 80% methanol was added to the
plate, and cells were scraped into solvent and transferred to a 1.5 mL tube. For
quantitation experiments, internal standard containing a mix of

13

C labeled metabolites

was added at this time. Samples were then sonicated and spun down, and the
supernatants were dried down under nitrogen. The dried samples were then
resuspended in 100

L of 5% sulfosalicylic acid and analyzed by liquid chromatography-

high resolution mass spectrometry as reported (Guo et al., 2016) with the only
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modification that the LC was coupled to a Q Exactive-HF with a heated ESI source
operating in negative ion mode alternating full scan and MS/MS modes. The [M-H]- ion
of each analyte and its internal standard was quantified, with peak confirmation by
MS/MS. Data analysis was conducted in Thermo XCalibur 3.0 Quan Browser and
FluxFix (Trefely et al., 2016). For quantitation experiments, samples were normalized
first to peak integrations of 13C-labeled internal standard components and then to protein
content in the sample, measured by BCA assay. Relative quantification was then
calculated by normalizing to the control condition in each experiment.
For glucose labeling experiments, cells were cultured in DMEM without glucose,
glutamine, or phenol red supplemented with 10 mM [U-13C]-glucose (Cambridge
Isotopes, CLM-1396-1), 4 mM glutamine, and 10% dialyzed fetal bovine serum. Cells
were incubated for the indicated time, and samples were prepared as above. For
GlcNAc labeling experiments, cells were cultured in DMEM without glucose, glutamine,
or phenol red supplemented with 10 mM N-[1,2-13C2]acetyl-D-glucosamine (13C
GlcNAc) (Omicron Biochemicals, GLC-006), 4 mM glutamine, 10 mM glucose, and 10%
dialyzed fetal bovine serum. Cells were incubated for the indicated time, and samples
were prepared as above.
Soft agar colony formation assay
Cells were trypsinized and counted using a Bright-Line hemacytometer (Sigma,
Z359629). The bottom agar layer was prepared by adding Bacto Agar (BD Bioscience,
214050) to cell culture media for a final concentration of 0.6%. 2 mL bottom agar was
added to each well of a 6-well tissue culture plate. Once bottom agar solidified, top layer
agar was prepared by combining trypsinized cells with the bottom agar mix for a final
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concentration of 0.3% Bacto Agar. 1 mL top layer agar was added to each well with a
bottom layer of agar. Cells were plated 2.5x104 per well. 0.5 mL DMEM high glucose
with 10% calf serum was added to cells every 7 days. Images were taken after 3 weeks.
Images were blinded and colonies per image were counted using ImageJ (Schneider et
al., 2012).
2D Proliferation assay
Cells were plated 3.5x104 per well of a 6-well plate. For each day that counts were
recorded, three wells were trypsinized and cells were counted twice using a
hemocytometer (Sigma, Z359629). The average of the two counts was recorded for
each well, and the average count of the three wells was used to graph the data. For
proliferation assays in 0.05 mM glutamine, trypan blue was used during cell counts.
Bioinformatics data analysis
The PDAC expression profiling dataset (GEO accession GSE16515, Pei et al., 2009)
from NCBI GEO Profile database (Edgar et al., 2002) was used to compare the
expression level between human normal and PDAC tumor samples. The dataset
consists of 52 samples, in which 16 samples are matched tumor and normal tissues, and
20 samples are only tumor tissues. The statistical analysis was conducted by one-way
ANOVA, the level of significance was evaluated by p < 0.01 and plotted in box-andwhisker diagram. Comparison of HBP gene expression between tumor (TCGA PAAD
dataset) and normal tissue (GTEx) was also conducted using GEPIA2 (Tang et al.,
2019).
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Tumor growth in vivo
3x106 PANC-1 NAGK CRISPR cells were injected with 1:1 Matrigel (Corning,
CB354248) into the flanks of NCr nude mice and measured with calipers once per week
for 22 weeks. At the experiment endpoint (22 weeks or when tumor reached 20 mm in
length), mice were euthanized with CO 2 and cervical dislocation. Tumors were removed,
weighed, cut into pieces for analysis, and frozen. All animal experiments were approved
by the University of Pennsylvania and the Institutional Animal Care and Use Committee
(IACUC).
Discussion
In this study, we identify a key role for NAGK in salvaging GlcNAc for UDPGlcNAc synthesis in PDA cells. We show that glutamine deprivation suppresses de novo
hexosamine biosynthesis and triggers post-translational modification of NAGK. NAGK
expression is elevated in human PDA tumors, and NAGK deficiency suppresses tumor
growth in mice. The data report a significant contribution of GlcNAc salvage to UDPGlcNAc pools in PDA cells and a role for NAGK in supporting tumor growth. This work
raises several key questions for future investigation.
First, the sources of GlcNAc salvaged by NAGK remain to be fully elucidated.
GlcNAc may be derived from recycling of GlcNAc following O-GlcNAc removal or
breakdown of a cell’s own N-glycans. Additionally, GlcNAc may be recovered from the
environment. Nutrient scavenging via macropinocytosis is a key feature of PDA
(Commisso et al., 2013; Kamphorst et al., 2015). Macropinocytosis has mostly been
associated with scavenging of protein to recover amino acids, but lysosomal break down
of glycoproteins may also release sugars including GlcNAc. Further, ECM components,
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including hyaluronic acid (HA), which is a polymer of GlcNAc and glucuronic acid
disaccharide units, may be additional sources of GlcNAc for salvage in the tumor
microenvironment. Indeed, in a manuscript co-submitted with this one, Kim and
colleagues identify HA as a major source of scavenged GlcNAc (Kim et al., submitted).
Further, the key fates of UDP-GlcNAc that support tumor growth remain to be
elucidated. Sufficient UDP-GlcNAc is required for protein glycosylation to maintain
homeostasis and prevent ER stress, particularly in a rapidly dividing cell. Additionally, a
wide range of cancers exhibit elevated O-GlcNAc, which could contribute to driving protumorigenic transcriptional and signaling programs. UDP-GlcNAc is also required for HA
synthesis, which is elevated in PanIN lesions and PDA compared to normal tissue
(Provenzano et al., 2012). Recently, it was shown that inhibiting the HBP by treatment
with 6-diazo-5-oxo-l-norleucine (DON) depletes HA and collagen in an orthotopic mouse
model. DON treatment also increased CD8 T-cell infiltration into the tumor, sensitizing
the tumor to anti-PD1 therapy (Sharma et al., 2020).
Finally, almost nothing is known about the role of NAGK and GlcNAc salvage in
normal physiology. Perhaps GlcNAc salvage is dispensable when nutrients are available
and cells are not dividing, as in most healthy tissues. However, in a tumor, in which cells
are proliferating and nutrients are spread thin, NAGK and GlcNAc salvage may become
more important in feeding UDP-GlcNAc pools.
In sum, in this work we report a key role for NAGK in feeding UDP-GlcNAc pools
in PDA cells and in supporting xenograft tumor growth. Further investigation will be
needed to elucidate the physiological functions of NAGK, as well as the mechanisms
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through which it supports tumor growth and its potential role in modulating therapeutic
responses.
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Figures

FIGURE 1: MGAT5-dependent N-glycans are minimally impacted by glucose or
glutamine deprivation in PDA cells. (A) Overview of the hexosamine biosynthesis
pathway (HBP). (B) O-GlcNAc levels in HCT-116 cells in high and low nutrients; cells
were incubated in indicated concentrations of glucose and glutamine for 48 hours. (C)
Phytohemagglutinin-L (LPHA) binding in colon cancer cells. Cells were incubated in the
indicated concentrations of glucose (left) or glutamine (right) for 48 hours and then
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analyzed by flow cytometry. Graph shows mean fluorescence intensity (MFI) relative to
control condition. (D-E) Phytohemagglutinin-L (LPHA) binding in pancreatic ductal
adenocarcinoma (PDA) cells in low nutrients. Cells were incubated in the indicated
concentrations of glucose (D) or glutamine (E) for 48 hours and then analyzed by flow
cytometry. Statistical significance was calculated by one-way ANOVA. (F) O-GlcNAc
levels in PDA cells in high and low nutrients. Cells were incubated in the indicated
concentrations of glucose or glutamine for 48 hours. For all bar graphs, mean +/standard error of the mean (SEM) of three biological triplicates is represented. Panels
(B)-(F) are representative of at least two independent experimental replicates. *, p ≤
0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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FIGURE 2: UDP-GlcNAc levels are maintained in low glutamine conditions despite
reduced de novo hexosamine synthesis. (A) Metabolite measurements in PANC-1
cells after culture for 48 hours in 0.05 mM glutamine. Quantification is normalized to 4
mM glutamine condition. Statistical significance was calculated by unpaired t-test. Mean
+/- SEM is represented. (B) Overview of the GlcNAc salvage pathway feeding into the
HBP. GlcNAc scavenged from O-GlcNAc removal or lysosomal breakdown of glycans
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can be phosphorylated by NAGK and used to regenerate UDP-GlcNAc. (C) Overview of
the incorporation of 13C glucose into UDP-GlcNAc. Different parts of the molecule can be
labeled from glucose-derived subunits, thus isotopologues up to M+16 can be derived
from glucose. To calculate the percent of metabolite with a labeled glucosamine ring,
isotopologues containing an M+6 isotopologue are added together (% labeled GlcN
equals sum of M+6, M+8, M+11, and M+13 for UDP-GlcNAc and sum of M+6 and M+8
for GlcNAc-P) (D) Percent of F-6-P, GlcNAc-P, and UDP-GlcNAc isotopologues
containing M+6 under the indicated concentrations of glutamine. In GlcNAc-P and UDPGlcNAc, the percent containing a labeled glucosamine ring, indicating de novo synthesis
of UDP-GlcNAc, is represented. All isotopologues are graphed in Figure S2.1. Statistical
significance was calculated by unpaired t-test. Mean +/- SEM is represented. *, p ≤ 0.05;
**, p ≤ 0.01; ***, p ≤ 0.001.
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FIGURE

3:

NAGK

(A) Measurement of

13

deletion

increases

de

novo

hexosamine

synthesis.

C GlcNAc labeled on the acetyl group into GlcNAc-P and UDP-

GlcNAc in NAGK knockout cells. Statistical significance was calculated by unpaired ttest comparing the mean incorporation of the two CRISPR clones and the empty vector
(EV) control. (B) Percent of F-6-P and GlcNAc-P isotopologues containing an M+6
isotopologue from

13

C glucose in PANC-1 (left) and MIA PaCa-2 (right) NAGK knockout

cells. Statistical significance was calculated by unpaired t-test comparing the mean
incorporation of the four CRISPR clones and the EV control. Mean +/- SEM of three
biological

replicates

is

represented.

(C)
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Percent

of

combined

UDP-GlcNAc

isotopologues containing an M+6 labeled glucosamine ring or M+5 labeled ribose from
UTP, calculated from S3.1 (E). Statistical significance was calculated by unpaired t-test
comparing the mean incorporation of the four CRISPR clones and the EV control. Mean
+/- SEM of three biological replicates is represented. (D) Measurement of HBP
metabolites in PANC-1 NAGK knockout cells cultured in the indicated concentrations of
glutamine. Statistical significance was calculated by unpaired t-test comparing the mean
incorporation of the four CRISPR clones and the EV control. Mean +/- SEM of four
biological replicates is represented. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.01.
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FIGURE 4: NAGK expression is increased in human PDA tumors and NAGK
knockout reduces tumor growth in vivo. (A) 2D proliferation assay by cell count in
PANC-1 and MIA PaCa-2 NAGK knockout cells. Mean +/- SEM of three technical
replicates is represented. Statistical significance was calculated using one-way ANOVA
at each time point. (B) Gene expression data for NAGK, GFPT1, PGM3, and UAP1 in
human PDA tumors compared with matched normal tissue. Statistical analysis was
conducted by one-way ANOVA, and level of significance was defined as p ≤ 0.01. (C)
Western blot for NAGK and HSP60 from lysate from subcutaneous tumors generated
from PANC-1 NAGK knockout cells in vivo. (D) Final tumor volume and (E) final tumor
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weight of subcutaneous tumors generated from PANC-1 NAGK knockout cells in vivo.
Cells were injected into the right flank of NCr nude mice and tumor volume was
calculated from caliper measurements. Statistical significance was calculated by oneway ANOVA comparing each mean to the EV control mean. Mean +/- SEM of biological
replicates is represented (n = 8 each group). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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Supplemental figures

SUPPLEMENTAL FIGURE S1: LPHA binding detects MGAT5-dependent glycans.
(A) Diagram of LPHA binding. LPHA recognizes specifically the β1-6 linkage established
by MGAT5. (B) LPHA binding on MGAT5 knockout cells isolated from a KPCY tumor (Li,
Byrne et al., 2018), representative flow plot and quantification. Graph shows MFI relative
to control cells. Statistical significance was calculated by unpaired t-test. (C)
Representative flow plots for LPHA binding graphed in Fig. 1D, E on PANC-1 cells in low
glucose and low glutamine. (D-E) LPHA binding in PDA cells in low nutrients Cells were
incubated in the indicated concentrations of serum (D) or oxygen (E) for 48 hours and
then analyzed by flow cytometry. Graph shows MFI relative to control condition.
Statistical significance was calculated by one-way ANOVA (D) and unpaired t-test (E).
Panels (B) – (E) are representative of at least two independent experimental replicates.
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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SUPPLEMENTAL FIGURE S2.1: De novo hexosamine synthesis is suppressed in
low glutamine conditions. (A) Metabolite measurements in MIA PaCa-2 cells after
culture for 48 hours in 0.05 mM glutamine. Quantification is normalized to 4 mM
glutamine condition. Statistical significance was calculated by unpaired t-test. Mean +/SEM of four biological replicates is represented. (B) Measurement of HBP metabolites in
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PANC-1 cells after cuture for 48 hours in 5 mM or 0.1 mM glucose. Mean +/- SEM of
four (5 mM) or five (0.1 mM) biological replicates is represented. Statistical significance
was calculated by unpaired t-test comparing each low glucose condition to the 10 mM
glucose control in each experiment. (C) Measurement of

13

C glucose incorporation into

UDP-GlcNAc in high and low glutamine. Mean +/- SEM of three biological replicates is
represented. (D) Measurement of

13

C glucose incorporation into GlcNAc-P in high and

low glutamine. Mean +/- SEM of three biological replicates is represented. (E)
Measurement of

13

C glucose into fructose-6-phosphate in high and low glutamine. Mean

+/- SEM of three biological replicates is represented. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤
0.001.
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SUPPLEMENTAL FIGURE S2.2: Uridine is also salvaged in low glutamine.
(A) Measurement of incorporation of

13

C glucose into uridine triphosphate (UTP) in high

and low glutamine. Mean +/- SEM of three biological replicates is represented. (B)
Measurement of metabolites in PANC-1 cells after transfection with the indicated siRNAs
and incubation in 4 mM or 0.05 mM glutamine for 48 hours. Mean +/- SEM of four
biological replicates is represented. (C) Gene expression of the indicated genes in
PANC-1 cells after transfection with the indicated siRNAs and incubation in 4 mM or
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0.05 mM glutamine for 48 hours. Mean +/- SEM of four biological replicates is
represented. (D) Measurement of incorporation of

13

C glucose into UDP-GlcNAc in

PANC-1 cells transfected with the indicated siRNAs and incubated in 4 mM or 0.05 mM
glutamine for 48 hours. Mean +/- SEM of three biological replicates is represented. (E)
Gene expression of the indicated genes in PANC-1 cells after transfection with the
indicated siRNAs and incubation in 4 mM or 0.05 mM glutamine for 48 hours. Mean +/SEM of three biological replicates is represented. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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SUPPLEMENTAL FIGURE S2.3: NAGK protein expression does not increase in low
glutamine despite increase in NAGK gene expression. (A) Gene expression of the
indicated genes in PDA cell lines after incubation in 4 mM or 0.05 mM glutamine for 48
hours. Mean +/- SEM of three biological replicates is represented. Statistical significance
was determined by unpaired t-test. (B) Gene expression of the indicated genes in PDA
cell lines after incubation in 10 mM or 0.1 mM glucose for 48 hours. Mean +/- SEM of
three biological replicates is represented. Statistical significance was determined by
unpaired t-test. (C) Western blot for NAGK in low nutrient conditions. MIA PaCa-2 cells
were cultured in the indicated glutamine concentrations and lysates were prepared with
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or without phosphatase inhibitors. Exogenous phosphatase was added to lysate after
harvest. A band shift is observed for NAGK in lysates without phosphatase inhibitors. (D)
Western blot for NAGK immunoprecipitated from MIA PaCa-2 cells cultured in the
indicated conditions. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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SUPPLEMENTAL FIGURE S3.1: NAGK knockout cells show increased enrichment
of

13

C glucose into hexosamine intermediates. (A) Gene expression of NAGK in

PANC-1 NAGK CRISPR cells. Mean +/- SEM of three biological replicates is
represented. Statistical significance was determined by one-way ANOVA. (B) Western
blot for NAGK and HSP60 in PANC-1 (left) and MIA PaCa-2 (right) NAGK CRISPR
knockout cells. (C) Measurement of incorporation of
69

13

C GlcNAc labeled on the acetyl

group into UDP-GlcNAc in PANC-1 NAGK knockout cells. Mean +/- SEM of three
biological replicates is represented. Statistical significance was determined by unpaired
t-test comparing siCon and siGALK2 for each clone. (D) Measurement of incorporation
of

13

C glucose into GlcNAc-P in NAGK knockout cells. Mean +/- SEM of three biological

replicates is represented. (E) Measurement of incorporation of

13

C glucose into UDP-

GlcNAc in NAGK knockout cells. Mean +/- SEM of three biological replicates is
represented.
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SUPPLEMENTARY FIGURE S3.2: UDP-GlcNAc levels are maintained in NAGK
knockout cells. (A) Measurement of HBP metabolites in MIA PaCa-2 NAGK knockout
cells cultured in 4 mM glutamine. Mean +/- SEM of four biological replicates is
represented. Statistical significance was calculated by unpaired t-test comparing the
mean of the three CRISPR clones and the empty vector control. (B) Gene expression of
NAGK in AsPC-1 cells transfected with shRNA against NAGK. One biological sample is
represented. (C) Incorporation of

13

C glucose into the glucosamine ring of UDP-GlcNAc

in PANC-1 cells transfected with the indicated shRNAs targeting NAGK. Mean +/- SEM
of three biological replicates is represented. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
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SUPPLEMENTARY FIGURE S4: NAGK knockout does not impair initial tumor
growth but ultimately limits tumor growth in vivo. (A) Soft agar colony formation in
NAGK knockout and control cells. Mean +/- SEM of three biological replicates is
represented. (B) Gene expression data plotted using GEPIA2 comparing TCGA
pancreatic cancer samples with TCGA normal pancreas samples and GTEx data.
Differential analysis between tumor and normal tissues was analyzed by one-way
ANOVA. *, p < 0.05. (C) Tumor volume of NAGK knockout tumors at earlier time points
in the experiment. Initial growth of NAGK knockout cells in vivo was comparable to
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control cells, but over time NAGK knockout tumors either stopped growing or regressed.
(D) LPHA binding in tumor sample lysates analyzed by Western blot. Blot for HSP60 as
loading control.
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Tables
TABLE 1: Primer sequences

CRISPR

qPCR

Primers
GFPT1 forward

CTCTGGCTTTGGTGGATAAA

GFPT1 reverse

GCAACCACTTGCTGAAGA

NAGK forward

GTGCTCATATCTGGAACAGG

NAGK reverse

ACCCTCATCACCCATCATA

HPRT forward

ATTATGCCGAGGATTTGGAA

HPRT reverse

CCCATCTCCTTCATGACATCT

RPL19 forward

CAAGAAGGAGGAGATCATCAAG

RPL19 reverse

ATCACAGAGGCCAGTATGTA

sgMGAT5 mouse forward

CACCGGCTGTCATGACACCAGCGTA

sgMGAT5 mouse reverse

AAACTACGCTGGTGTCATGACAGCC

sgNAGK#1 forward

CACCGTTGACGTAGCCGATATCATG

sgNAGK#1 reverse

AAACCATGATATCGGCTACGTCAAC

sgNAGK#2 forward

CACCGTGCTTGGTGTGCGATCCAGT

sgNAGK#2 reverse

AAACACTGGATCGCACACCAAGCAC
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CHAPTER 4: Discussion and future directions
Considering salvage and recycling in cancer metabolism
A key principle in cancer metabolism is that rapidly dividing tumor cells need to
generate biomass in addition to ATP for energy. In normal proliferating cells, in healthy
tissue regulated by growth factor signaling where nutrients are readily available, glucose
and glutamine are catabolized to provide the carbon required to generate another cell.
However, while there is some debate as to the actual concentrations of glucose,
glutamine, and other useful metabolites in the PDA tumor microenvironment (Kamphorst
et al., 2015; Sullivan et al., 2019), these tumors in general are not properly vascularized
and it is likely that different regions of the tumor experience different nutritional contexts.
In regions where nutrients are scarce, another hallmark of tumor metabolism, “use of
opportunistic modes of nutrient acquisition,” becomes more important (Pavlova and
Thompson, 2016). Autophagy and macropinocytosis are more direct routes to biomass
accrual in that these mechanisms can recycle biomass that’s already been generated.
Indeed, strategies to target

lysosomal

degradation pathways are still under

consideration, though autophagy inhibitors have had variable effects in clinical trials and
macropinocytosis is difficult to target specifically (Matthews et al., 2011; Mulcahy Levy et
al., 2017).
While it is well accepted that cancer cells use these scavenging and recycling
pathways more than normal cells, it is not well studied how much material cancer cells
generate through reusing and repurposing existing biomass relative to how much is
synthesized de novo in vivo. Further, while there has been much focus on the lysosome,
enzymes such as NAGK, UCK1/2, and ACSS2 act outside of the lysosome to recycle
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nutrients and are be critical to transforming metabolites to a form usable for biosynthesis
(Bulusu et al., 2017; Suzuki et al., 2004). If cancer cells are more dependent than normal
cells on these non-lysosomal salvage enzymes, targeting enzymes like NAGK could be
a more specific and viable strategy to block salvage of key metabolites like GlcNAc,
rather than targeting the lysosome which is critical for normal cells as well.
Understanding the proportional contribution of biomass recycling to cancer cell
metabolism and the key metabolic units generated this way could point to more effective
strategies for targeting metabolic pathways in cancer.
Possible sources of UDP-GlcNAc
As mentioned earlier, GlcNAc may be derived from recycling of GlcNAc following
O-GlcNAc removal or breakdown of a cell’s own N-glycans. However, since tumor cells
are proliferative, they likely need to recover additional GlcNAc from the environment.
Nutrient scavenging via macropinocytosis is a hallmark of PDA (Commisso et al., 2013;
Kamphorst et al., 2015). Macropinocytosis has mostly been associated with scavenging
of protein to recover amino acids, but lysosomal break down of glycosylated proteins
most likely also releases sugars including GlcNAc (Winchester, 2005). The significant
desmoplasia in the PDA microenvironment could potentially be a huge source of GlcNAc
and other sugars for glycosylation. ECM components, such as laminin, collagen, and
fibronectin, are heavily glycosylated. Further, the glucosaminoglycan hyaluronic acid
(HA) is a polymer of GlcNAc and glucuronic acid disaccharide units, and thus may be a
significant additional source of GlcNAc. While the breakdown and use of sugars
recovered from scavenged glycans has not been well studied, it was demonstrated that
matrix-attached breast epithelial cells either grown in nutrient restricted media in vitro or
in mammary tissue of mice on a restricted diet take up extracellular laminin via β4
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integrin (Muranen et al., 2017). While sugars were not measured, laminin uptake did
increase intracellular amino acid levels in vitro. Another study showed in ovarian cancer
cells that when α5β1 integrins, the major fibronectin-binding integrin, are endocytosed,
fibronectin is taken up into the cell also. It was noted that high expression of the proteins
required for α5β1 integrin endocytosis correlated with poor survival in PDA patients
(Rainero et al., 2015). While this was attributed to increased invasiveness of cells with
active endocytosis of α5β1 integrin demonstrated in vitro, the contribution of fibronectin
uptake to cell metabolism was not assessed and remains a question for further study.
Another possible source of GlcNAc is uptake of necrotic cell debris. While
necrocytosis has not been studied in PDA, it was shown in macropinocytic breast cancer
cells that supplementation of necrotic cell debris could provide cells with both lipids and
nucleotides, reducing their sensitivity to treatments targeting fatty acid or nucleotide
synthesis in vitro. Genetic inhibition of macropinocytosis resulted in slower growth of
orthotopic tumors generated from murine mammary tumor cells and improved sensitivity
of these tumors to 5-FU treatment (Jayashankar and Edinger, 2020). Given that PDA
cells are highly macropinocytic, it would be interesting to examine whether necrotic
debris is contributing to cell metabolism in pancreatic cancer, especially whether
necrocytosis also supplies the cells with GlcNAc.
The role of UDP-GlcNAc in supporting tumor growth
While both GFPT1 and NAGK are upregulated in human PDA, it is not clear what
fates of UDP-GlcNAc support tumor growth. UDP-GlcNAc is itself a key substrate in
glycosylation, especially in O-GlcNAcylation, and it is also a precursor for many of the
other sugars used in glycosylation, such as UDP-GalNAc and sialic acid. Sufficient UDP77

GlcNAc is necessary for protein glycosylation to maintain homeostasis and prevent ER
stress. A wide range of cancers exhibit elevated O-GlcNAc and tumor tissue samples
often display increased and modified N-glycosylation (Dennis and Laferte, 1989; Dennis
et al., 1987; Lau and Dennis, 2008; Stowell et al., 2015). However, despite these
observations, it is not well understood what function, if any, this elevated glycosylation
has in cancer cell survival and tumor growth.
To understand the role of elevated O-GlcNAc in cancer, it will be critical to
identify how OGT substrate specificity is achieved and what proteins are differentially OGlcNAcylated in disease tissue. Studies in recent years demonstrate that OGlcNAcylation of specific proteins can help mediate tumor growth and metastasis. For
example, Snail1, a transcriptional repressor of E-cadherin, is stabilized by OGlcNAcylation in a glucose-dependent manner. In breast cancer cells, O-GlcNAcylation
of Snail1 promotes migration and invasion in vitro (Park et al., 2010). Similarly, OGlcNAcylation of Yes-associated protein 1 (YAP), a core component of the Hippo
signaling pathway, promotes its translocation to the nucleus where it can associate with
its binding partner TEAD and enable expression of target genes. Disruption of YAP OGlcNAcylation by mutating the modification site limits growth of pancreatic cancer cells
in vitro and in vivo (Peng et al., 2017). Thus, it is likely that O-GlcNAcylation of specific
proteins is promoting PDA cell survival and growth, though these targets have not been
identified. OGT itself is upregulated in many cancers (Ferrer et al., 2016), and
maintenance of UDP-GlcNAc levels would ensure that there is adequate substrate for
the enzyme. While inhibition of OGT or OGA would likely have too many off tar get
effects to be a treatment option in patients, new in vitro strategies are being developed
to target O-GlcNAcylation or O-GlcNAc removal on specific proteins using nanobody78

fused OGT or OGA (Ge et al., 2021; Ramirez et al., 2020). These tools can be used to
better understand the role of O-GlcNAcylation of specific proteins in vitro and perhaps
someday could reach the clinic.
The effects of increased N-glycosylation are less clear. Maintenance of UDPGlcNAc levels likely play at least a partial role in maintaining high levels of N-glycans
because certain glycan modifications are sensitive to changes in UDP-GlcNAc levels.
Complex N-glycans established by MGAT5, which were introduced at the beginning of
Chapter 3, show a dose-dependent response to GlcNAc supplementation in mammary
tumor cells (Lau et al., 2007). This happens because MGAT5 has a very low affinity for
UDP-GlcNAc, which renders it sensitive to changes in concentration of the metabolite.
These MGAT5-dependent N-glycans are particularly important to cell membrane
proteins with extracellular domains because they interact with the galectin lattice and
thus can promote retention of a protein at the cell surface. Further, the localization of a
particular protein at the cell surface is dependent in part on the number of glycosylation
sites per extracellular length on that protein. As demonstrated in vitro, proteins with low
numbers of N-glycosylation sites, such as glucose transporter GLUT1, show a sigmoidal
response to increasing concentrations of GlcNAc and shift from “off” to “on” over a small
GlcNAc concentration range. Proteins with higher numbers of N-glycosylation sites, such
as epidermal growth factor receptor EGFR, show a logarithmic response to increasing
concentrations of GlcNAc and increase localization at the surface with GlcNAc
concentration in a dose-dependent manner (Lau et al., 2007). In principle, this could be
a mechanism through which cells adjust to changes in nutritional context, as membrane
proteins are important for nutrient uptake and communicating signals from the
environment. However, such a model would require that GlcNAc concentration increases
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or decreases in accordance with nutrient availability, and that expression of specific Nglycosylation enzymes does not change. It is interesting, then, that PDA cells leverage
GlcNAc salvage via NAGK in low glutamine to maintain UDP-GlcNAc levels, and in low
glucose PDA cells clearly have other mechanisms for maintaining key glycosylation
features. Further, expression of GFPT1 and MGAT5 both increase in the context of
mutant KRAS (Ying et al., 2012), which could push the cells further out of sync with their
environment. Comparative proteomics of membrane proteins in PDA cells versus a
normal epithelial cell line such as HPDE could identify whether certain proteins are
enriched at the cancer cell surface, and that could begin to point to the functionality of
increased N-glycosylation in cancer.
Outside of glycosylation, UDP-GlcNAc is also required for synthesis of HA, a
polymer of disaccharide units consisting of UDP-GlcNAc and D-glucuronic acid, which is
synthesized from UDP-GlcNAc. While HA was previously discussed in this section as a
potential source of UDP-GlcNAc for tumor cells, it is unknown what cell type produces
HA in a PDA tumor and thus it is possible UDP-GlcNAc plays a bigger role as a
substrate for HA synthesis in tumor cells. HA is present in low amounts in normal
pancreas but increases in PanIN lesions and PDA (Provenzano et al., 2012). PDA cells
are capable of producing HA in vitro (Mahlbacher et al., 1992). Depletion of fibroblasts in
an autochthonous PDA mouse model results in a decrease in collagen I but not HA in
the tumor microenvironment, indicating that HA must be generated by another cell type,
possibly the tumor cells themselves (Özdemir et al., 2014). Previous studies
demonstrated that treatment of PDA with exogenous hyaluronidase can increase
vascularization and improve drug delivery to the tumor (Jacobetz et al., 2013;
Provenzano et al., 2012), although a phase III clinical trial reported no improvement in
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overall patient survival when combining pegylated hyaluronidase with nab-paclitaxel plus
gemcitabine (Cutsem et al., 2020). Recently, it was shown that inhibiting the HBP by
treatment with 6-diazo-5-oxo-l-norleucine (DON) depletes HA and collagen in an
orthotopic mouse model. DON treatment also increased CD8 T-cell infiltration into the
tumor, which suggests a role for HA generation in immune evasion (Sharma et al.,
2020). Thus, as opposed to a cell intrinsic pro-tumorigenic role, maintenance of UDPGlcNAc pools may also provide substrate to generate an unfavorable microenvironment
for immune response.
The role of GlcNAc recycling in development and homeostasis
Almost nothing is currently known about the role of NAGK and GlcNAc salvage in
normal physiology. Even in non-cancerous IL-3-dependent hematopoietic cells, a
substantial proportion of the UDP-GlcNAc pool remains unlabeled from 13C-glucose
(Wellen et al., 2010), suggesting that salvage may contribute to UDP-GlcNAc pools in a
variety of cell types even when nutrients are available. However, while GFPT1 is
required for embryonic development in mice, NAGK knockout mouse embryos are viable
(Dickinson et al., 2016).
NAGK deficiency has not yet been characterized in postnatal or adult mice. A few
studies have been done in lower organisms and in cells. Disruption of NAGK expression,
whether by silencing or overexpression, changes expression of Wnt reporter genes and
causes defective anterior-posterior patterning in Xenopus embryos. Further, NAGK
knockdown decreases Wnt signaling in drosophila and produces phenotypes consistent
with Wnt suppression in zebrafish. NAGK inhibition also impedes viability of human
intestinal crypt-derived organoids, which require a Wnt-dependent stem cell niche.
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Addition of a Wnt activator rescued the viability of the organoids, again indicating that
the effects of NAGK knockdown are mediated through Wnt (Neitzel et al., 2019).
Altogether these results suggest that there is a conserved relationship between NAGK,
GlcNAc recycling, and Wnt signaling. Given these phenotypes, while NAGK-deficient
mouse embryos may be viable, it is likely they would display developmental defects.
Studies of NAGK function in mature cells is limited, but a series of papers showed that in
neurons NAGK interacts with dynein to promote axonal growth and can increase
clearance of harmful protein aggregates in the brain. However, this role for NAGK is
independent of its kinase activity and thus is unlikely to be related to UDP-GlcNAc
generation (Islam et al., 2015; Ripon et al., 2020; Sharif et al., 2016).
So, then, what is the role of NAGK in normal adult tissue? Perhaps GlcNAc
salvage is dispensable when nutrients are available and cells are not dividing, as in most
healthy tissues. However, in a tumor, in which cells are proliferating and nutrients are
spread thin, NAGK and GlcNAc salvage may become more important in feeding UDPGlcNAc pools. Related questions include through what mechanisms does glutamine
deprivation lead to upregulation of salvage via NAGK, and are other hexosamine
salvage enzymes important in generating substrates for glycosylation? In this study, we
did not observe upregulation of NAGK at the protein level, but we did observe a band
shift for NAGK in low nutrient conditions indicative of a post-translational modification.
While experiments to test for phosphorylation were inconclusive, it is known that NAGK
is phosphorylated in platelets upon thrombin activation, though this modification is not
yet functionally characterized (Maguire et al., 2002). Additionally, GALK2 is also
upregulated in low glutamine and can compensate, albeit minimally, for NAGK in KO
cells. As UDP-GalNAc is also a key substrate for glycosylation, it would be interesting to
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study whether GALK2 and GalNAc salvage also play a role in sustaining PDA tumor
growth.
UDP-GlcNAc generation as a therapeutic target
As the HBP is upregulated in a wide range of cancers, it naturally has been
examined as a therapeutic target. Two commonly used inhibitors against GFPT1 are 6diazo-5-oxo-l-norleucine (DON) and azaserine, both of which are glutamine analogs that
broadly inhibit aminotransferases. Because these compounds impact many other
enzymes besides GFPT1, it is unlikely that they would be successful as therapeutics, but
studies using these drugs demonstrate proof that targeting the hexosamine pathway can
inhibit cancer growth. It was recently shown that DON treatment can inhibit growth of
orthotopic PDA tumors in immunocompetent mice. Importantly, DON treatment reduced
the amount of HA in the PDA microenvironment and allowed for immune cell infiltration,
thus rendering the tumors vulnerable to anti-PD1 treatment (Sharma et al., 2020). Thus,
by determining the key downstream outputs of the pathway, targeting the HBP holds
promise for improving the efficacy of other therapeutics.
Another consideration is whether some tumor types may be more susceptible to
HBP inhibition than others. For example, non-small cell lung adenocarcinomas with comutations in KRAS and LKB1 are acutely sensitive to GFPT2 inhibition, whether genetic
inhibition or use of azaserine (Kim et al., 2020). This is an interesting case because
these tumor cells are dependent on GFPT2, as opposed to GFPT1 which is the isoform
present in most cell types. If GFPT2 can be targeted specifically, that could be a viable
strategy for cancers reliant on this isoform.
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The findings of the study presented in Chapter 3 suggest that in addition to de
novo hexosamine synthesis, targeting of hexosamine salvage warrants further
investigation in terms of potential for therapeutic intervention. The structure of human
NAGK is known (Weihofen et al., 2006) and a sugar analog inhibitor, 3-O-methyl-Nacetyl-D-glucosamine, is commercially available (Zeitler et al., 1992). Though it has not
been widely used and has not been tested in vivo, this inhibitor is promising because it
has so far been shown to be quite specific for NAGK and does not inhibit other
glucokinases (Zeitler et al., 1992). As the role of NAGK in different cancer types is more
fully elucidated, it may become clear that some cancers are more dependent on salvage
than de novo UDP-GlcNAc generation and vice-versa, and this could guide therapeutic
strategies for targeting one or the other. Another strategy would be to target both the
HBP and salvage pathway arms. An inhibitor targeting PGM3, which converts GlcNAc-6P to GlcNAc-1-P and is thus required for both de novo UDP-GlcNAc synthesis and
GlcNAc recycling, showed efficacy in treating gemcitabine-resistant patient-derived
xenograft PDA models (Ricciardiello et al., 2020), as well as in breast cancer xenografts
(Ricciardiello et al., 2018).
Concluding remarks

In sum, the work presented here identifies a previously unappreciated
contribution of GlcNAc recycling to UDP-GlcNAc pools in PDA cells. Further study of
GlcNAc salvage via NAGK will lead to better understanding of the HBP as a nutrient
sensing pathway in PDA and other contexts, as production of UDP-GlcNAc is not
necessarily wholly dependent on glucose and glutamine availability. As the HBP is
activated across cancer types, future work to understand the role of UDP-GlcNAc
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generation in sustaining cancer cells overall could point to new therapeutic targets and
strategies for many diseases, including PDA.
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